,NCTId,AgreementOtherDetails,AgreementPISponsorEmployee,AgreementRestrictionType,AgreementRestrictiveAgreement,ArmGroupDescription,ArmGroupInterventionName,ArmGroupLabel,ArmGroupType,AvailIPDComment,AvailIPDId,AvailIPDType,AvailIPDURL,BaselineCategoryTitle,BaselineClassDenomCountGroupId,BaselineClassDenomCountValue,BaselineClassDenomUnits,BaselineClassTitle,BaselineDenomCountGroupId,BaselineDenomCountValue
0,NCT04371159,0,0,0,0,Each participant will test their urine sample using the Velieve U.S. device,Device: Velieve U.S.,Velieve U.S.,Experimental,0,0,0,0,0,0,0,0,0,0,0
1,NCT04474496,0,0,0,0,Marshallese persons 18 years of age or older residing in the United States,Other: Assessing impact of COVID19,Marshallese in the U.S.,0,0,0,0,0,0,0,0,0,0,0,0
2,NCT02801266,0,0,0,0,"['The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.', 'The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.']",Behavioral: Evidence informed birth control counseling,"['Intervention', 'No intervention']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
3,NCT01599390,0,0,0,0,0,Other: Data collection,Influenza Group,0,0,0,0,0,0,0,0,0,0,0,0
4,NCT00312702,0,No,0,No,"['Falciparum Malaria Protein 11 with AS02A adjuvant', 'Falciparum Malaria Protein 11 with AS02A adjuvant']","['Biological: Falciparum Malaria Protein 11 with AS02A adjuvant', 'Biological: Falciparum Malaria Protein 11 with AS02A adjuvant']","['10µg dose FMP011', '50µg dose FMP011']","['Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male', 'Hispanic or Latino', 'Not Hispanic or Latino', 'Unknown or Not Reported', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,United States,"['BG000', 'BG001', 'BG002', 'BG003']","['5', '13', '1', '19']"
5,NCT00312663,0,No,0,No,"['Falciparum Malaria Protein 11 with AS01B adjuvant', 'Falciparum Malaria Protein 11 with AS01B adjuvant']","['Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.', 'Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.']","['10ug dose FMP011', '50ug dose FMP011']","['Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,United States,"['BG000', 'BG001', 'BG002', 'BG003']","['5', '13', '6', '24']"
6,NCT01153880,0,0,0,0,"['Age at time of prescription was <9 months', 'Age at time of prescription was uncertain for <9 months', 'Age at time of prescription was 9 months to 6 years', 'Age at time of prescription was 7 to 18 years', 'Age at time of prescription was 19 to 65 years', 'Age at time of prescription was 66 years and older']","['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']","['Age <9 months definitive', 'Age <9 months uncertain', '9 months to 6 years', '7 to 18 years', '19 to 65 years', '66 years and older']",0,0,0,0,0,0,0,0,0,0,0,0
7,NCT02019732,0,0,0,0,"Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.",Other: Data collection,Study Group,0,0,0,0,0,0,0,0,0,0,0,0
8,NCT03972358,0,0,0,0,"Mifepristone 200 mg orally on day 1.

Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone).","['Drug: Mifepristone', 'Drug: Misoprostol']",Medical menstrual regulation,Experimental,0,0,0,0,0,0,0,0,0,0,0
9,NCT00948233,0,0,0,0,"['Educational video game', 'Pamphlets on stopping tobacco use']","['Behavioral: Video Game', 'Behavioral: Surveys', 'Behavioral: Pamphlet', 'Behavioral: Surveys']","['Intervention', 'Standard Care']",0,0,0,0,0,0,0,0,0,0,0,0
10,NCT00026728,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,NCT01211990,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,NCT02663219,0,0,0,0,"['The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.', 'Standard of care']",Behavioral: Intervention,"['Intervention', 'Control']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
13,NCT00121108,0,0,0,0,"['Placebo', 'MEDI-524']","['Other: Placebo', 'Biological: MEDI-524']","['2', '1']","['Placebo Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
14,NCT01861210,0,0,0,0,"['Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.', 'Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention\'s ""Fundamentals of HIV Prevention Counseling"" training.']","['Behavioral: Couples Voluntary HIV Counseling and Testing', 'Behavioral: Individual Counseling and Testing']","['Couples Counseling and Testing', 'Individudal Counseling and Testing']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
15,NCT02911155,0,0,0,0,radiologic technologists certified in nuclear medicine,0,US Nuclear Medicine Technologist,0,0,0,0,0,0,0,0,0,0,0,0
16,NCT00724867,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['Belimumab 1 mg/kg IV every 28 days', 'Belimumab 10 mg/kg IV every 28 days']","['Biological: Belimumab 1 mg/kg', 'Biological: Belimumab 10 mg/kg']","['Belimumab 1 mg/kg', 'Belimumab 10 mg/kg']","['Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male']",0,0,0,"['Black or African American/African Heritage', 'American Indian or Alaska Native', 'Asian: Central Asian Heritage', 'Asian: East Asian Heritage', 'Asian: Japanese Heritage', 'Asian: South Asian Heritage', 'Asian: Southeast Asian Heritage', 'Native Hawaiian or Other Pacific Islander', 'White: Middle East/North African Heritage', 'White: White/Caucasian/European Heritage', 'Mixed Race']",BG000,268
17,NCT03973905,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).\n\nThis post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).\n\nThis post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.']","['Other: Not applicable / dataset analysis', 'Other: Not applicable / dataset analysis']","['Pertussis Case Group', 'Control Group']",0,0,0,0,0,"['Female', 'Male']",0,0,0,"[""Infant's age (weeks)"", 'White', 'Black', 'Other-unspecified']","['BG000', 'BG001', 'BG002']","['107', '183', '290']"
18,NCT00340457,0,0,0,0,"['African American patients with renal cancer from two geographic areas of the US', 'African American participants without renal cancer from two geographic areas of the US']",0,"['Cases', 'Controls']",0,0,0,0,0,0,0,0,0,0,0,0
19,NCT02429284,0,0,0,0,"Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.",0,Patients newly diagnosed with CTEPH,0,0,0,0,0,0,0,0,0,0,0,0
20,NCT02889263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,NCT03995745,0,0,0,0,"[""Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period."", 'Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.']",Behavioral: Medication adherence and financial incentives,"['adherence based financial incentives', 'control']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
22,NCT00928694,"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['Fenofibrate U.S. Formulation', 'Fenofibrate UK Formulation']","['Drug: fenofibrate (U.S. formulation)', 'Drug: fenofibrate (UK formulation)']","['1', '2']","['Active Comparator', 'Active Comparator']",0,0,0,0,"['Female', 'Male']",0,0,0,0,BG000,14
23,NCT02153996,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,NCT00413673,0,0,0,0,PRK,Procedure: PRK,1,Experimental,0,0,0,0,0,0,0,0,0,0,0
25,NCT03867409,0,0,0,0,"['Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.', 'Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.', 'Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.', 'Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.']","['Behavioral: message delivered via virtual technology', 'Behavioral: message delivered via virtual technology', 'Behavioral: message delivered via virtual technology', 'Behavioral: message delivered via virtual technology']","['Concordant virtual human', 'Dis-concordant virtual human', 'Concordant text', 'Dis-concordant text']","['Experimental', 'Experimental', 'Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
26,NCT04004260,0,0,0,0,"['The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.', 'The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.']","['Behavioral: Internet-based Cognitive Behavior Therapy', 'Behavioral: Internet-based Cognitive Behavior Therapy']","['Experimental group', 'Weekly check-in control group']","['Experimental', 'Other']",0,0,0,0,0,0,0,0,0,0,0
27,NCT04205877,0,0,0,0,All participants will have the same data collected at the same time points.,Device: Transcatheter PDA Closure,Registry Group,0,0,0,0,0,0,0,0,0,0,0,0
28,NCT01262079,0,0,0,0,0,0,"['Group 1: 6-15 years old', 'Group 2: 16-25 years old', 'Group 3: 26-35 years old', 'Group 4: 36-45 years old', 'Group 5: 46-55 years old', 'Group 6: 56-65 years old', 'Group 7: 66-75 years old', 'Group 8: 76-85 years old', 'Group 9: > 85 years old']",0,0,0,0,0,0,0,0,0,0,0,0
29,NCT00646438,0,0,0,0,"['strict glucose control (study arm)', 'standard insulin treatment (control arm)']",Drug: Strict Glycemic Control for one year post-op CABG,"['1', '2']","['Active Comparator', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
30,NCT00341588,0,0,0,0,"['Male U.S. serviceman, age 18-45 years old with TGCT', 'Male U.S. serviceman, age 18-45 years old without TGCT']",0,"['Cases', 'Controls']",0,0,0,0,0,0,0,0,0,0,0,0
31,NCT04562636,0,0,0,0,"['Four environmental messages from the Meatless Monday campaign.', 'Four health messages from the Meatless Monday campaign.', ""Four neutral messages about checking one's credit score.""]","['Other: Environmental message', 'Other: Health message', 'Other: Neutral Message']","['Environment-focused Meatless Monday messages', 'Health-focused Meatless Monday messages', 'Neutral Message']","['Experimental', 'Experimental', 'Other']",0,0,0,0,0,0,0,0,0,0,0
32,NCT03924505,0,0,0,0,"['This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.', 'This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.']","['Behavioral: Implementation Manual with External Facilitation Intervention', 'Behavioral: Implementation Manual only']","['Implementation Manual and External Facilitation', 'Implementation Manual - only']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
33,NCT02334462,0,0,0,0,"['Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530', 'Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.', 'Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530', 'Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.', 'Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530', 'Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.', 'Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530']","['Biological: Pfs25M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel', 'Drug: TWINRIX', 'Drug: Menactra']","['Group 1- Mali', 'Group 1-U.S', 'Group 2- Mali', 'Group 2-U.S', 'Group 3- Mali', 'Group 3- U.S.', 'Group 4- Mali']","['Experimental', 'Experimental', 'Experimental', 'Experimental', 'Experimental', 'Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
34,NCT03311295,0,0,0,0,0,Device: ARTO System,ARTO System,Experimental,0,0,0,0,0,0,0,0,0,0,0
35,NCT03242278,0,0,0,0,"['NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)', 'NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)']","['Drug: Rivaroxaban (Xarelto, BAY59-7939)', 'Drug: Rivaroxaban (Xarelto, BAY59-7939)']","['NVAF patients receiving 20 mg rivaroxaban', 'NVAF patients receiving 15 mg rivaroxaban']",0,0,0,0,0,0,0,0,0,0,0,0
36,NCT03683134,0,0,0,0,"['Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.', 'Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.']","['Behavioral: Mediterranean diet', 'Dietary Supplement: Olive oil and mixed nuts', 'Behavioral: American Heart Association']","['Mediterranean diet group', 'American Heart Association group']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
37,NCT04047316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,NCT03952364,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,NCT04021030,0,0,0,0,0,Behavioral: Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),Experimental,0,0,0,0,0,0,0,0,0,0,0
40,NCT02959827,0,No,OTHER,Yes,"Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent",Drug: Iodinated contrast agents,Iodinated contrast agents,0,0,0,0,0,"['<1 month', '1 to 3 months', '3 to 6 months', '6 months to 1 year', '1 to 4 years', 'Female', 'Male', 'White', 'African American', 'Hispanic', 'Asian/Pacific islander', 'Other or missing']",0,0,0,0,BG000,2320
41,NCT02395536,0,No,0,Yes,"['Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.', 'Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.']","['Other: office setting', 'Other: hosptial setting']","['In office Outside walls of hospital', 'Traditional Hospital Setting']","['Experimental', 'Other']",0,0,0,0,"['Female', 'Male']","['BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002']","['251', '231', '482', '251', '231', '482', '0', '0', '0', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482']","['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']",United States,"['BG000', 'BG001', 'BG002']","['251', '231', '482']"
42,NCT03628235,0,0,0,0,"['CAG length ≥ 40; DCL = 4, TFC ≥ 11', 'CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10', 'CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6']","['Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey']","['Early stage HDGECs', 'Middle stage HDGECs', 'Late stage HDGECs', 'Companions of early stage HDGECs', 'Companions of middle stage HDGECs', 'Companions of late stage HDGECs']",0,0,0,0,0,0,0,0,0,0,0,0
43,NCT02787538,0,0,0,0,"[""The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option."", 'The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.']","['Behavioral: US-ANSWER-2 decision aid', 'Behavioral: Control group (Online medication guide)']","['US-ANSWER-2 decision aid', 'Control group (Online medication guide)']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
44,NCT01290393,0,0,0,0,"['Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.', 'Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.']","['Other: Data collection', 'Other: Data collection']","['Exposed vaccinated cohort', 'Non-exposed vaccinated cohort']",0,0,0,0,0,0,0,0,0,0,0,0
45,NCT04263311,0,0,0,0,"['There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.', 'There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes']",Behavioral: CHW,"['Community Health Workers (CHW) treatment group', 'Control group']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
46,NCT00875641,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.']","['Other: Health Insurance Database', 'Other: Health Insurance Database', 'Other: Health Insurance Database']","['HRV cohort', 'Concurrent Control cohort', 'Recent Historical Control cohort']",0,0,0,0,0,"['Female', 'Male', 'Northeast', 'South/Southeast', 'Midwest', 'West']",0,0,0,US Geographic Region,"['BG000', 'BG001', 'BG002', 'BG003']","['57931', '173384', '159344', '390659']"
47,NCT03199846,0,0,0,0,"['Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma', 'Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.', 'Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.', 'Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.', 'Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016', 'Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016']","['Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional']","['advanced melanoma patients', 'Ipi monotherapy', 'Ipi + nivo combination therapy', 'Dabrafenib + trametinib combination therapy', 'Pembro monotherapy', 'Nivo monotherapy']",0,0,0,0,0,0,0,0,0,0,0,0
48,NCT04587245,0,0,0,0,Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients,Other: Online questionnaire and interviews,Physicians,0,0,0,0,0,0,0,0,0,0,0,0
49,NCT02773979,0,0,0,0,"['Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1', 'CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1', 'CQ/PfSPZ Challenge 102400 sporozoites N=9']","['Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge', 'Other: Placebo', 'Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge', 'Other: Placebo', 'Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge']","['Group 1: PfSPZ 51200 sporozoites/Placebo', 'Group 2: PfSPZ 102400 sporozoites/Placebo', 'Group 3: PfSPZ 102400 sporozoites']","['Active Comparator', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
50,NCT03274726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,NCT01283828,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,NCT04191824,0,0,0,0,"['Immediate return of results to inform participant of APOL1 status (either positive or negative).', 'Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.']","['Diagnostic Test: APOL1 status', 'Diagnostic Test: APOL1 status']","['Immediate Return of Results', 'Delayed Return of Results']","['Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
53,NCT03197688,0,0,0,0,Not applicable as non-interventional study,Other: Notapplicable,Notapplicable,0,0,0,0,0,0,0,0,0,0,0,0
54,NCT02813577,"Prior to PI publication of site results, sponsor requires publication of multi-centers results.",No,OTHER,Yes,This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.,Device: Lutonix® 035 Drug Coated Balloon PTA Catheter,Lutonix® 035 Drug Coated Balloon PTA Catheter,Other,0,0,0,0,"['Female', 'Male', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,"['≥18 years of age', 'United States']",BG000,4
55,NCT00666380,0,0,0,0,0,"['Biological: Plasmodium falciparum Malaria Protein 010 (FMP010)', 'Biological: Plasmodium falciparum Malaria Protein 010 (FMP010)']","['10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant', '50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
56,NCT01287247,0,0,0,0,"['The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.', 'The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.']","['Biological: Xeomin®', 'Biological: Xeomin®']","['Cervical Dystonia', 'Blepharospasm']",0,0,0,0,0,0,0,0,0,0,0,0
57,NCT04163341,0,0,0,0,0,Behavioral: Adapted Common Elements Treatment Approach,"['CETA protocol', 'Enhanced Usual Care']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
58,NCT02987335,0,0,0,0,"['N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.', 'N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp', 'N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp', 'N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp']","['Drug: Pancreatic Clamp', 'Drug: Pancreatic Clamp', 'Drug: Pancreatic Clamp', 'Drug: Pancreatic Clamp']","['Lean Diabetes Subjects', 'Type 2 Diabetes Mellitus Subjects', 'Type 1 Diabetes Mellitus Subjects', 'Nondiabetic Subjects']",0,0,0,0,0,0,0,0,0,0,0,0
59,NCT02867722,0,0,0,0,Patients will receive daylight-PDT treatment (aminolevulinic acid),Drug: aminolevulinic acid HCl,Daylight PDT,Experimental,0,0,0,0,0,0,0,0,0,0,0
60,NCT03276637,0,0,0,0,"Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.",Genetic: Whole exome sequencing,Healthy Active-Duty Airmen Cohort,Experimental,0,0,0,0,0,0,0,0,0,0,0
61,NCT03192891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,NCT03373045,0,0,0,0,"To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.",0,Cohort of US adults with severe asthma,0,0,0,0,0,0,0,0,0,0,0,0
63,NCT04229212,0,0,0,0,"['No drainage', 'a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed']","Device: hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)","['No drainage', 'Drainage']","['No Intervention', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
64,NCT02848781,0,0,0,0,"['Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.', 'Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.', 'The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.']","['Device: Implantable Cardioverter Defibrillator (ICD)', 'Procedure: Catheter Ablation', 'Device: Implantable Cardioverter Defibrillator (ICD)', 'Procedure: Catheter Ablation']","['ICD with Ablation', 'ICD Only', 'Ablation Only (Registry)']","['Experimental', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
65,NCT00385047,0,0,0,0,"['FMP 2.1 50 μg FMP2.1/AS01B', 'FMP 2.1 50 μg FMP2.1/AS02A']","['Biological: Group A FMP2.1/AS01B', 'Biological: Group B FMP2.1/AS02A']","['Group A', 'Group B']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
66,NCT02993120,0,0,0,0,"['For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.', '• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.', 'For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks']",0,"['Cohort 1', 'Cohort 2', 'Cohort 3']",0,0,0,0,0,0,0,0,0,0,0,0
67,NCT03045120,0,0,0,0,"['Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.', 'Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.', 'Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.', 'Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.']",0,"['dasatinib cohort', 'imatinib cohort', 'nilotinib cohort', 'bosutinib cohort']",0,0,0,0,0,0,0,0,0,0,0,0
68,NCT01154296,0,No,0,No,"['Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.']",Behavioral: RESPECT-2 Counseling,"['Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,"['<25 years', '>=25 years', 'Male sex', 'Female sex', 'Black', 'Hispanic', 'White', 'Other', 'United States']","['BG000', 'BG001', 'BG002']","['2505', '2507', '5012']"
69,NCT02857764,0,0,0,0,"['Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.', 'Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.', 'Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.', 'Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.', 'Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.']",0,"['Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users', 'Canagliflozin New Users', 'Dapagliflozin New Users', 'Empagliflozin New Users', 'First-time Non-SGLT2i AHA New Users']",0,0,0,0,0,0,0,0,0,0,0,0
70,NCT00412568,0,0,0,0,PRK control group,Procedure: Photorefractive Keratectomy (PRK),1,Active Comparator,0,0,0,0,0,0,0,0,0,0,0
71,NCT03353480,0,0,0,0,"['250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US', '250mg Azithromycin tablet manufactured at Pfizer Dalian, China']","['Drug: Azithromycin Tablet manufactured in US', 'Drug: Azithromycin Tablet manufactured in China']","['Reference', 'Experimental']","['Other', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
72,NCT00800267,0,0,0,0,0,"['Drug: fixed combination latanoprost-timolol', 'Drug: latanoprost 0.005%', 'Drug: timolol 0.5%']","['Fixed combination of latanoprost 0.005% and timolol 0.5%', 'latanoprost 0.005%', 'Timolol - 0.5%']","['Experimental', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
73,NCT00601835,"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.",No,OTHER,Yes,"['Participants received Canadian manufactured Td vaccine', 'Participants received US manufactured Td vaccine']","['Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine', 'Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine']","['Canadian Td Vaccine Group', 'United States Td Vaccine Group']","['Experimental', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002']","['2950', '700', '3650']"
74,NCT01087905,0,No,0,No,"['Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks', 'Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks', 'Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks\n\n2 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks\n\n2 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks', 'Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks', 'Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks\n\n6 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks\n\n6 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.']","['Drug: Nicotine patch', 'Drug: Nicotine patch', 'Behavioral: CMAC', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Behavioral: CMAC', 'Drug: Nicotine patch', 'Drug: Nicotine patch', 'Behavioral: CMAC', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Behavioral: CMAC']","['2 Weeks of Nicotine Patch Only, No CMAC', '2 Weeks of Nicotine Patch Only plus CMAC', '2 Wks Nicotine Patch+Nic Gum, No CMAC', '2 Wks Nicotine Patch+Nic Gum plus CMAC', '6 Weeks of Nicotine Patch Only, No CMAC', '6 Weeks of Nicotine Patch Only plus CMAC', '6 Wks Nicotine Patch+Nic Gum, No CMAC', '6 Wks Nicotine Patch+Nic Gum plus CMAC']","['Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002', 'BG003', 'BG004', 'BG005', 'BG006', 'BG007', 'BG008']","['119', '126', '123', '122', '122', '127', '121', '127', '987']"
75,NCT02616198,0,0,0,0,"['EquiaFil G-coat combination was applied on one randomly selected cavity to be restored', 'EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored', 'River SC G-coat combination was applied on one randomly selected cavity to be restored', 'River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored']","['Other: EquiaFil Fuji Varnish', 'Other: Riva SC G-coat', 'Other: Riva SC Fuji Varnish', 'Other: EquiaFil G-coat', 'Other: Riva SC G-coat', 'Other: Riva SC Fuji Varnish', 'Other: EquiaFil G-coat', 'Other: EquiaFil Fuji Varnish', 'Other: Riva SC Fuji Varnish', 'Other: EquiaFil G-coat', 'Other: EquiaFil Fuji Varnish', 'Other: Riva SC G-coat']","['EquiaFil G-coat', 'EquiaFil Fuji Varnish', 'Riva SC G-coat', 'Riva SC Fuji Varnish']","['Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
76,NCT00007540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,NCT02163525,0,0,0,0,"['Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)', 'Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)']","['Procedure: Global Fibroid Ablation (GFA)', 'Procedure: Uterine Artery Embolization (UAE)', 'Procedure: Global Fibroid Ablation (GFA)', 'Procedure: Abdominal or Laparoscopic Myomectomy']","['Ablation vs Embolization', 'Ablation vs Myomectomy']","['Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
78,NCT03310112,0,0,0,0,"['Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.', 'Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.', 'Participants will receive no intervention but will be tested before and after a no-training interval.']","['Behavioral: 4-week MBAT', 'Behavioral: 2-week MBAT']","['4-week MBAT', '2-week MBAT', 'No training control (NTC)']","['Experimental', 'Active Comparator', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
79,NCT02766634,0,0,0,0,0,"['Biological: Filgrastim Hospira (US)', 'Biological: U.S.-approved Neupogen®', 'Biological: Filgrastim Hospira (US)', 'Biological: U.S.-approved Neupogen®']","['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
80,NCT02971709,0,0,0,0,"['Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.', 'Passive recreation areas in public parks that remained unshaded at pretest and posttest.']",Behavioral: Shade Sail,"['Shade Sail', 'Unshaded Control']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
81,NCT03801928,0,0,0,0,"['Group treated with Inflectra for Ulcerative Colitis', ""Group treated with Inflectra for Crohn's Disease""]","['Drug: Inflectra', 'Drug: Inflectra']","['Ulcerative Colitis', ""Crohn's Disease""]",0,0,0,0,0,0,0,0,0,0,0,0
82,NCT01641029,0,0,0,0,"Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.",Other: No intervention,pyelonephritis,0,0,0,0,0,0,0,0,0,0,0,0
83,NCT02128542,"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:

The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years",No,OTHER,Yes,Participants will receive sofosbuvir+RBV for 12 weeks.,"['Drug: Sofosbuvir', 'Drug: RBV']",Sofosbuvir+RBV 12 weeks,Experimental,0,0,0,0,"['Female', 'Male']",0,0,0,"['Black or African American', 'White', 'Hawaiian or Pacific Islander', 'Other', 'United States', 'CC', 'CT', 'TT', '< 800,000 IU/mL', '≥ 800,000 IU/mL', 'Genotype 2', 'Genotype 2b', 'Genotype 2a/2c', 'No', 'Yes']","['BG000', 'BG001', 'BG002']","['47', '19', '66']"
84,NCT00573976,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,NCT00306007,0,0,0,0,"['English speaking women recruited from the general OB/GYN clinic', 'Spanish speaking (monolingual) women recruited from the general OB/GYN clinic', 'English speaking women recruited from the abortion clinic', 'Spanish speaking (monolingual) women recruited from the abortion clinic']",0,"['English prenatal', 'Spanish prenatal', 'English abortion clinic', 'Spanish abortion clinic']",0,0,0,0,0,0,0,0,0,0,0,0
86,NCT02766647,0,0,0,0,0,"['Biological: Filgrastim Hospira (US)', 'Biological: US-approved Neupogen®', 'Biological: Filgrastim Hospira (US)', 'Biological: US-approved Neupogen®']","['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
87,NCT04460898,0,0,0,0,HR+/HER2- metastatic breast cancer patients in the US.,0,Breast Cancer Patients,0,0,0,0,0,0,0,0,0,0,0,0
88,NCT00413517,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,NCT02882100,0,0,0,0,"['NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents', 'NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents']","['Biological: adjuvanted trivalent influenza vaccine', 'Biological: trivalent influenza vaccine', 'Biological: trivalent influenza vaccine']","['aTIV', 'TIV']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
90,NCT00533975,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,NCT02109757,0,0,0,0,"['This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.', 'This group will not receive software intervention prior to and after one-on-one education, only afterwards.']","['Other: Software intervention and education', 'Other: Education only']","['Software intervention and education', 'Education only']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
92,NCT00959933,0,0,0,0,"['Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)', 'Rebetol 200 Capsules (Schering Corporation, U.S.A.)']","['Drug: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)', 'Drug: Rebetol 200 Capsules (Schering Corporation, U.S.A.)']","['1', '2']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
93,NCT00960479,0,0,0,0,"['Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)', 'Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)']","['Drug: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)', 'Drug: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)']","['1', '2']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
94,NCT03266497,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,NCT02207569,0,No,0,No,"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:

Evolut R Transcatheter Aortic Valve (TAV)
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
EnVeo R Loading System (LS)",Device: CoreValve Evolut R TAVR system,CoreValve Evolut R TAVR system,Experimental,0,0,0,0,"['Female', 'Male']",0,0,0,United States,BG000,241
96,NCT02569632,0,0,0,0,Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals),Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals),Open Label: MenB-FHbp,Experimental,0,0,0,0,0,0,0,0,0,0,0
97,NCT02069925,0,0,0,0,"['This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis', 'This intervention will provide equivalent best practice care without the benefit of an early detection campaign']","['Behavioral: Early Detection (ED)', 'Behavioral: Usual Detection', 'Behavioral: Usual Detection']","['Early Detection (ED)', 'Usual Detection']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
98,NCT03433131,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,NCT02746809,0,No,0,No,Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.,Device: CoreValve Evolut 34R TAVR system,CoreValve Evolut 34R TAVR system,Experimental,0,0,0,0,"['Female', 'Male']","['BG000', 'BG000', 'BG000', 'BG000']","['60', '60', '0', '60']","['Participants', 'Participants', 'Participants', 'Participants']",United States,BG000,60
100,NCT00328380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,NCT04552535,0,0,0,0,"['Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))', 'Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))']","['Drug: Second line (2L) afatinib', 'Drug: Second line chemotherapy']","['Second line (2L) afatinib', 'Second line (2L) chemotherapy']",0,0,0,0,0,0,0,0,0,0,0,0
102,NCT03293875,0,0,0,0,"['Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.', 'Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.']","['Behavioral: Encuentro', 'Behavioral: Encuentro']","['HIV testing promoted by members of the social network', 'Peer network behavioral intervention']","['Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
103,NCT01235260,0,0,0,0,"['Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)', 'Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)']","['Drug: Becaplermin users', 'Other: Becaplermin nonusers']","['001', '002']",0,0,0,0,0,0,0,0,0,0,0,0
104,NCT03390660,0,0,0,0,"born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014",Other: WIC program participation,birth cohorts,0,0,0,0,0,0,0,0,0,0,0,0
105,NCT00837499,0,0,0,0,0,"['Behavioral: Questionnaire', 'Behavioral: Questionnaire', 'Behavioral: Questionnaire']","['Mexican Women from Mexico', 'Mexican-American Women in U.S.', 'African-American Women in U.S.']",0,0,0,0,0,0,0,0,0,0,0,0
106,NCT01629537,0,0,0,0,"['Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.', 'Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.']","['Procedure: Placebo Procedure', 'Procedure: Stellate Ganglion Block injection with ropivicane']","['Placebo', 'Stellate Ganglion Block (SGB)']","['Other', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
107,NCT00351741,0,Yes,0,No,"['Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation', 'Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation']","['Device: Ventilation - High Frequency Percussive Ventilation', 'Device: Ventilation - ARDSnet']","['High Frequency', 'Conventional']","['Experimental', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002']","['31', '31', '62']"
108,NCT01965561,0,Yes,0,0,"['Use of Combat Ready Clamp (CRoC)', 'Use of Abdominal Aortic and Junctional Tourniquet', 'Junctional Emergency Treatment Tool', 'SAM Junctional Tourniquet']","['Device: CRoC', 'Device: AAJT', 'Device: JETT', 'Device: SJT']","['CRoC', 'AAJT', 'JETT', 'SJT']","['Experimental', 'Experimental', 'Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male']",0,0,0,0,BG000,10
109,NCT01927835,0,0,0,0,"['Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.']","['Biological: DNA-HIV-PT123 vaccine', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: Placebo for DNA/NYVAC/AIDSVAX', 'Biological: DNA-HIV-PT123 vaccine', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: Placebo for DNA/NYVAC/AIDSVAX', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: Placebo for DNA/NYVAC/AIDSVAX', 'Biological: Placebo for DNA/NYVAC/AIDSVAX']","['Group 1A: Treatment', 'Group 1B: Treatment', 'Group 2A: Treatment', 'Group 2B: Treatment', 'Group 3A: Placebo', 'Group 3B: Placebo']","['Experimental', 'Experimental', 'Experimental', 'Experimental', 'Placebo Comparator', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
110,NCT01704235,0,0,0,0,medical physicians and nurse practitioners,Other: Demographic Form and Semi-Structured Interview Guide,Primary health care providers,0,0,0,0,0,0,0,0,0,0,0,0
111,NCT01306266,0,0,0,0,"['initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo', 'Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg']","['Drug: Rizatriptan', 'Drug: Placebo']","['rizatriptan', 'Placebo']","['Active Comparator', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
112,NCT00796315,"The Investigator and Sub-Investigators agree that all data, calculations, interpretations, opinions, and recommendations regarding the study will be the property of the Sponsor. The Investigator agrees to consider the results as information subject to confidentiality and use restrictions.",No,OTHER,Yes,Doxylamine Succinate United States Pharmacopeia (USP),Drug: Doxylamine Succinate USP,Doxylamine Succinate (USP),Experimental,0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years']",0,0,0,"['Subjects Aged 2-5 years', 'Subjects Aged 6-11 years', 'Subjects Aged 12-17 years', 'Male, Ages 2-5', 'Female, Ages 2-5', 'Male, Ages 6-11', 'Female, Ages 6-11', 'Male, Ages 12-17', 'Female, Ages 12-17', 'United States']",BG000,41
113,NCT00005463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,NCT03382418,0,0,0,0,"['Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.', 'Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.', 'Participants will receive placebo at Day 0 and Months 2 and 6.']","['Biological: gp145 C.6980 Vaccine', 'Biological: Aluminum Hydroxide Adjuvant', 'Biological: gp145 C.6980 Vaccine', 'Biological: Aluminum Hydroxide Adjuvant', 'Biological: Placebo']","['Group 1: gp145 C.6980 (high dose)', 'Group 2: gp145 C.6980 (low dose)', 'Group 3: Placebo']","['Experimental', 'Experimental', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
115,NCT00054743,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,NCT00730964,0,No,0,No,Open Label,"Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)",Phase 4,Other,0,0,0,0,"['Female', 'Male']",0,0,0,"['<=65 years', 'Between 65 and 75 years', '>=75 years', 'United States']",BG000,1039
117,NCT02886689,0,0,0,0,"['patients will be those receiving any biotherapy', 'patients will be those not receiving biotherapy : non indication, refusal, contraindication.']",Drug: TNF-alpha antagonist and other biotherapy,"['1', '2']",0,0,0,0,0,0,0,0,0,0,0,0
118,NCT00005455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,NCT01150695,0,0,0,0,"['Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.', 'Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.']","['Other: Placebo', 'Biological: Undiluted Francisella tularensis live attenuated vaccine', 'Other: Placebo', 'Biological: Undiluted Francisella tularensis live attenuated vaccine']","['Group A (DVC-LVS)', 'Group B (USAMRIID-LVS)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
120,NCT00245076,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,NCT00935623,0,0,0,0,"['The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).', 'If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.']","['Biological: Malaria Challenge', 'Biological: Malaria Challenge']","['Cohort 1', 'Cohort 2']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
122,NCT03688126,0,0,0,0,"['Lifestyle modification program that is developed by the participant to meet his/her specific needs.', 'Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.']","['Behavioral: Self-Guided Lifestyle Intervention', 'Behavioral: Structured Lifestyle Intervention']","['Self-Guided Lifestyle Intervention', 'Structured Lifestyle Intervention']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
123,NCT02053506,0,0,0,0,"['This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.', 'This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).']","['Dietary Supplement: Immune-enhancing nutritional beverage', 'Dietary Supplement: Placebo (for nutritional beverage and probiotic)', 'Dietary Supplement: Probiotics (BB-12)', 'Dietary Supplement: Placebo (for nutritional beverage and probiotic)']","['Immune-enhancing nutritional beverage', 'Probiotics (BB-12)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
124,NCT03933215,0,0,0,0,"No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.",Drug: Cladribine Tablets,Cladribine Tablets,0,0,0,0,0,0,0,0,0,0,0,0
125,NCT03933202,0,0,0,0,"No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.",Drug: Cladribine Tablets,Cladribine Tablets,0,0,0,0,0,0,0,0,0,0,0,0
126,NCT00005171,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,NCT01256164,Investigators were part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.,No,OTHER,Yes,"['After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.']","['Device: Fibrocaps (fibrin sealant)', 'Device: Gelfoam']","['Fibrocaps + Gelfoam', 'Gelfoam']","['Experimental', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002']","['47', '23', '70']"
128,NCT03631472,0,0,0,0,"RheOx Treatment (i.e., Bronchial Rheoplasty)",Device: RheOx,RheOx Treatment,Experimental,0,0,0,0,0,0,0,0,0,0,0
129,NCT03699709,0,0,0,0,0,"Behavioral: Budgeting, purchasing and cooking educational intervention","['Intervention Arm', 'Control Arm']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
130,NCT00237263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,NCT02939131,0,No,0,No,"['Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)']","['Behavioral: Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm', 'Behavioral: Enhanced Standard of Care']","['COMB-R', 'Enhanced Standard of Care']","['Experimental', 'Active Comparator']",0,0,0,0,"['12-18 yrs', '19-24 yrs', 'Female', 'Male', 'White, non-Hispanic', 'Black, Non- Hispanic', 'Hispanic, regardless of race', 'Asian, Pacific Islander', 'More than one race', 'Missing/Unknown', 'Perinatal', 'Behavioral', 'not taking medications', 'taking psychiatric medications']",0,0,0,"['Age, categorized', 'Race/Ethnicity', 'United States']","['BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002']","['81', '75', '156', '6', '7', '13']"
132,NCT03488264,0,0,0,0,"['50 participants will be recruited from the United States.', '50 participants will be recruited from Jamaica.']",0,"['United States', 'Jamaica']",0,0,0,0,0,0,0,0,0,0,0,0
133,NCT01873482,0,0,0,0,Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.,Behavioral: Movement to rhythm,Movement with rhythm,Experimental,0,0,0,0,0,0,0,0,0,0,0
134,NCT02829073,0,0,0,0,"['Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.', 'Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.']","['Device: Neuromonics Tinnitus Treatment Program', 'Device: Placebo Device']","['Oasis™ device', 'Placebo device']","['Experimental', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
135,NCT01369030,0,No,0,No,Subjects with depression who have been prescribed Deplin® daily.,Other: Deplin®,Deplin®,0,0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years']",0,0,0,"['Female', 'Male', 'United States']",BG000,554
136,NCT01568424,0,No,OTHER,Yes,Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.,Device: CentriMag RVAS placement,Treatment Group,Other,0,0,0,0,"['Female', 'Male']",0,0,0,0,BG000,25
137,NCT02406599,0,0,0,0,"['The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.', 'The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.']","['Device: Margin Probe', 'Other: Control: Additional inspection']","['SOC + Device', 'SOC + Additional Inspection']","['Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
138,NCT03965195,0,0,0,0,"['Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff', 'Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff']","['Biological: Recombinant Influenza Vaccine', 'Biological: Standard Dose Quadrivalent Influenza Vaccine']","['RIV4', 'IV4']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
139,NCT01368549,0,0,0,0,Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.,Other: Metanx® (a medical food),Metanx®,0,0,0,0,0,0,0,0,0,0,0,0
140,NCT01370954,0,0,0,0,Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.,Other: CerefolinNAC®,CerefolinNAC®,0,0,0,0,0,0,0,0,0,0,0,0
141,NCT01339546,0,0,0,0,"All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study",Other: no intervention,Study population,0,0,0,0,0,0,0,0,0,0,0,0
142,NCT02252159,0,0,0,0,"['Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:\n\nWatchful waiting (with or without aspirin)*, or\nPhlebotomy (PHL) alone (with or without aspirin)* - or\nHU alone (without concomitant PHL, with or without aspirin).\n\n(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)', ""Patients with clinically overt PV, with one or more of the following disease characteristics:\n\nTreatment with HU and PHL in combination or\nTreatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or\nA history of thrombosis (venous or arterial) or\nA history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or\nPresence of documented splenomegaly (clinically assessed by palpation) or\n\nPresence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)\n\nTiredness\nDifficulty sleeping\nItching\nMuscle aches and/or bone pain\nNight sweats\nSweats while awake\nOther""]",0,"['Cohort A', 'Cohort B']",0,0,0,0,0,0,0,0,0,0,0,0
143,NCT04072289,0,0,0,0,"['0.25D and 0.50D cylinder treatments will be measured and treated by the laser.', '0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.']",Device: Visumax spherocylindrical treatment,"['Low cylinder (treatment)', 'Low cylinder (no treatment)']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
144,NCT04423770,0,0,0,0,Dentists in the United States,Other: No intervention,U.S. dentists,0,0,0,0,0,0,0,0,0,0,0,0
145,NCT01358552,0,0,0,0,Subjects who have been prescribed Néevo/NéevoDHA® daily.,Other: Néevo®/ NéevoDHA®,Néevo®/NéevoDHA®,0,0,0,0,0,0,0,0,0,0,0,0
146,NCT02856646,0,0,0,0,Community Sample,0,Population with Condition,0,0,0,0,0,0,0,0,0,0,0,0
147,NCT01940679,0,0,0,0,"['Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.', 'Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production', 'Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.', 'Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.']","['Dietary Supplement: encapsulated 600 mg EPA/DHA', 'Dietary Supplement: encapsulated 600 mg EPA/DHA', 'Dietary Supplement: encapsulated 600 mg EPA/DHA', 'Dietary Supplement: encapsulated 600 mg EPA/DHA']","['Fresh meat stick', 'Stored meat stick', 'Fresh pound cake', 'Stored pound cake']","['Experimental', 'Experimental', 'Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
148,NCT02951598,0,0,0,0,"['Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.', 'Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.', 'Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.', 'Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.']","['Drug: Florbetapir F 18 PET Scan', 'Drug: Florbetapir F 18 PET Scan', 'Drug: Florbetapir F 18 PET Scan', 'Drug: Florbetapir F 18 PET Scan']","['MCI (Amyloid Positive)', 'Mild AD Dementia (Amyloid Positive)', 'MCI (Amyloid Negative)', 'Mild Dementia (Amyloid Negative)']","['Other', 'Other', 'Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
149,NCT02988934,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,NCT01028300,"Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication prior to the intended submission, presentation, or publication date",No,OTHER,Yes,0,Device: ProDisc™-L Total Disc Replacement (TDR),ProDisc L,Other,0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,BG000,4
151,NCT01034865,0,0,0,0,"['Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.', 'Patients with chronic liver disease without evidence of HCC']",0,"['HCC PTS', 'LD']",0,0,0,0,0,0,0,0,0,0,0,0
152,NCT02352532,0,0,0,0,0,"['Other: Dry Needling', 'Other: Sham Needling', 'Other: Dry Needling']","['Low Back Pain - Dry Needling', 'Low Back Pain - Sham', 'Asymmptomatic - Dry Needling']","['Experimental', 'Sham Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
153,NCT03198793,0,0,0,0,Capsules of QGC001 250 mg,Drug: QGC001,QGC001,Experimental,0,0,0,0,0,0,0,0,0,0,0
154,NCT01112917,0,No,GT60,Yes,Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.,"['Device: VenaTech Convertible Vena Cava Filter', 'Procedure: Vena Cava Filter Conversion']",VenaTech Convertible Vena Cava Filter,Experimental,0,0,0,0,"['Female', 'Male', 'Hispanic or Latino', 'Not Hispanic or Latino', 'Unknown or Not Reported', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,United States,BG000,149
155,NCT01764269,0,0,0,0,"['Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)', 'Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)']","['Other: text message surveillance for fever', 'Other: text message surveillance for fever']","['inactivated influenza vaccine (IIV)', 'Live attenuated influenza vaccine (LAIV)']","['Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
156,NCT03346603,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,NCT04281290,0,0,0,0,0,Procedure: Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP),Experimental group,Experimental,0,0,0,0,0,0,0,0,0,0,0
158,NCT04601103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,NCT04600856,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,NCT04599907,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,NCT04593875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,NCT04589507,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,NCT04586205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,NCT04585646,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,NCT04584788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,NCT04584099,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,NCT04577898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,NCT04577456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,NCT04569253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,NCT04567186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,NCT04562532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,NCT04558970,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,NCT04558632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,NCT04558047,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,NCT04557917,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,NCT04557891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,NCT04556968,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,NCT04556474,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,NCT04547920,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,NCT04547712,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,NCT04544670,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,NCT04542525,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,NCT04540913,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,NCT04537013,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,NCT04536168,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,NCT04534764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,NCT04532099,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,NCT04529616,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,NCT04529109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,NCT04524247,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,NCT04523545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,NCT04513574,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,NCT04510857,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,NCT04508335,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,NCT04502758,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,NCT04501146,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,NCT04500821,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,NCT04499521,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,NCT04496752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,NCT04493021,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,NCT04488666,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,NCT04483791,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,NCT04476784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,NCT04474054,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,NCT04469218,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,NCT04466930,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,NCT04455997,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,NCT04455854,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,NCT04450108,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,NCT04437615,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,NCT04422990,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,NCT04419714,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,NCT04409158,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,NCT04403542,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,NCT04400643,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,NCT04394546,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,NCT04388787,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,NCT04388722,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,NCT04386785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,NCT04378764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,NCT04377438,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,NCT04338971,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,NCT04335981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,NCT04332640,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,NCT04330001,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,NCT04324593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,NCT04320823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,NCT04319887,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,NCT04318132,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,NCT04314947,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,NCT04314700,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,NCT04313725,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,NCT04310566,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,NCT04307446,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,NCT04306744,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,NCT04305119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,NCT04303273,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,NCT04299386,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,NCT04299009,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,NCT04298359,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,NCT04296773,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,NCT04295499,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,NCT04287036,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,NCT04285541,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,NCT04281940,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,NCT04279522,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,NCT04277455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,NCT04263532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,NCT04252183,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,NCT04247581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,NCT04244357,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,NCT04243369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,NCT04243239,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,NCT04239885,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,NCT04237207,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,NCT04236869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,NCT04230486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,NCT04224155,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,NCT04223609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,NCT04220060,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,NCT04219891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,NCT04211441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,NCT04210622,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,NCT04207749,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,NCT04206839,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,NCT04206384,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,NCT04203745,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,NCT04202419,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,NCT04201340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,NCT04200898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,NCT04196907,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,NCT04195581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,NCT04194307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,NCT04192630,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,NCT04189913,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,NCT04189081,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,NCT04186806,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,NCT04184973,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,NCT04178720,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,NCT04177771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,NCT04177212,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,NCT04176965,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,NCT04175340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,NCT04166032,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,NCT04162652,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,NCT04158466,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,NCT04153292,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,NCT04152642,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,NCT04151992,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,NCT04151290,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,NCT04141007,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,NCT04136158,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,NCT04134286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,NCT04130490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,NCT04127188,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,NCT04121754,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,NCT04119609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,NCT04116879,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,NCT04116866,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,NCT04112784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,NCT04112628,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,NCT04112134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,NCT04106934,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,NCT04096495,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,NCT04087395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,NCT04085328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,NCT04083742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,NCT04082078,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,NCT04081727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,NCT04079842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,NCT04079816,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,NCT04078490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,NCT04073823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,NCT04069585,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,NCT04068818,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,NCT04065659,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,NCT04064606,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,NCT04060524,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,NCT04057105,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,NCT04056494,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,NCT04055519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,NCT04055324,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,NCT04054401,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,NCT04046627,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,NCT04043234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,NCT04040933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,NCT04036747,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
328,NCT04035161,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,NCT04033315,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,NCT04032977,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,NCT04031989,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
332,NCT04031976,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
333,NCT04030702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,NCT04011826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,NCT04008836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,NCT04005586,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,NCT04003831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
338,NCT03999944,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
339,NCT03997357,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,NCT03996187,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,NCT03995355,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
342,NCT03992768,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,NCT03991468,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,NCT03972995,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,NCT03971721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,NCT03969875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,NCT03967184,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,NCT03964831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,NCT03953274,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,NCT03950895,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,NCT03949335,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
352,NCT03944629,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
353,NCT03942016,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
354,NCT03941912,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
355,NCT03934463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,NCT03934125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,NCT03931213,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,NCT03925545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,NCT03920280,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,NCT03918928,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,NCT03912584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,NCT03911700,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,NCT03898778,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,NCT03897751,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,NCT03897712,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,NCT03895034,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,NCT03888352,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
368,NCT03872609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,NCT03872466,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,NCT03871179,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
371,NCT03864848,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,NCT03864081,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
373,NCT03862300,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,NCT03858140,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,NCT03851510,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,NCT03839199,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,NCT03835026,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,NCT03812679,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,NCT03805074,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,NCT03799549,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
381,NCT03790046,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
382,NCT03789669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
383,NCT03788551,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
384,NCT03782116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
385,NCT03779984,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
386,NCT03771521,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
387,NCT03771352,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,NCT03764254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,NCT03748823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,NCT03748771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,NCT03748316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
392,NCT03748264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
393,NCT03736798,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,NCT03730480,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,NCT03729024,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
396,NCT03728309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
397,NCT03716492,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
398,NCT03713281,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,NCT03708393,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
400,NCT03706430,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
401,NCT03704636,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
402,NCT03700372,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
403,NCT03700047,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
404,NCT03696316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
405,NCT03692741,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
406,NCT03685136,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
407,NCT03682432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,NCT03681886,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
409,NCT03681496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
410,NCT03678103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
411,NCT03677388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
412,NCT03670277,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
413,NCT03663010,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,NCT03642431,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
415,NCT03641937,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,NCT03631550,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
417,NCT03628898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
418,NCT03617822,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
419,NCT03614130,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
420,NCT03613363,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
421,NCT03611101,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
422,NCT03604900,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
423,NCT03604562,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
424,NCT03604432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
425,NCT03601182,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
426,NCT03600194,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
427,NCT03599271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
428,NCT03589911,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
429,NCT03586167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
430,NCT03578302,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
431,NCT03574259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
432,NCT03564366,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
433,NCT03560141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
434,NCT03550807,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
435,NCT03540576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
436,NCT03538561,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
437,NCT03525704,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
438,NCT03523208,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
439,NCT03508778,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
440,NCT03502200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
441,NCT03500341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
442,NCT03497910,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
443,NCT03488849,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
444,NCT03488238,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
445,NCT03482297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
446,NCT03477370,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
447,NCT03467204,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
448,NCT03465514,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
449,NCT03462576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
450,NCT03451786,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
451,NCT03442842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
452,NCT03441971,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
453,NCT03441880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
454,NCT03441477,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
455,NCT03439189,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
456,NCT03435224,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
457,NCT03435211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
458,NCT03431883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
459,NCT03423251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
460,NCT03421145,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
461,NCT03418545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
462,NCT03408444,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
463,NCT03388138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
464,NCT03384381,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
465,NCT03372434,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
466,NCT03372343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
467,NCT03371160,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
468,NCT03366194,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
469,NCT03351192,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
470,NCT03345121,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
471,NCT03345017,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
472,NCT03339388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
473,NCT03336944,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
474,NCT03329794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
475,NCT03323515,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
476,NCT03315117,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
477,NCT03299933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
478,NCT03275532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
479,NCT03272308,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
480,NCT03269097,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
481,NCT03268356,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
482,NCT03268265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
483,NCT03267134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
484,NCT03257410,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
485,NCT03251079,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
486,NCT03246503,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
487,NCT03242148,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
488,NCT03239574,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
489,NCT03236519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
490,NCT03235791,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
491,NCT03233945,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
492,NCT03230877,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
493,NCT03230747,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
494,NCT03219567,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
495,NCT03198988,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
496,NCT03190564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
497,NCT03182660,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
498,NCT03172949,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
499,NCT03150407,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
500,NCT03148613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
501,NCT03147820,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
502,NCT03147482,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
503,NCT03147417,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
504,NCT03143127,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
505,NCT03142594,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
506,NCT03142581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
507,NCT03138369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
508,NCT03138343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
509,NCT03134989,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
510,NCT03132363,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
511,NCT03132350,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
512,NCT03129152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
513,NCT03128840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
514,NCT03128632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
515,NCT03127566,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
516,NCT03127540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
517,NCT03127527,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
518,NCT03127501,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
519,NCT03127488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
520,NCT03125135,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
521,NCT03125122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
522,NCT03125109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
523,NCT03125096,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
524,NCT03125044,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
525,NCT03124992,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
526,NCT03124953,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
527,NCT03124940,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
528,NCT03124888,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
529,NCT03124849,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
530,NCT03124810,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
531,NCT03124745,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
532,NCT03124732,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
533,NCT03124719,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
534,NCT03124706,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
535,NCT03124264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
536,NCT03124251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
537,NCT03123380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
538,NCT03123341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
539,NCT03122379,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
540,NCT03120702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
541,NCT03100760,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
542,NCT03098602,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
543,NCT03073148,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
544,NCT03072186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
545,NCT03066063,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
546,NCT03038074,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
547,NCT03035318,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
548,NCT03034902,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
549,NCT03021707,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
550,NCT03021473,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
551,NCT03019107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
552,NCT03017742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
553,NCT03003767,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
554,NCT02995421,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
555,NCT02986789,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
556,NCT02972892,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
557,NCT02970799,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
558,NCT02966210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
559,NCT02957071,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
560,NCT02956928,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
561,NCT02948751,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
562,NCT02938637,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
563,NCT02922621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
564,NCT02919566,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
565,NCT02918942,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
566,NCT02916823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
567,NCT02913560,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
568,NCT02911376,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
569,NCT02910674,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
570,NCT02907203,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
571,NCT02904382,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
572,NCT02888626,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
573,NCT02872844,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
574,NCT02870959,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
575,NCT02870881,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
576,NCT02863796,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
577,NCT02863432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
578,NCT02862080,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
579,NCT02858089,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
580,NCT02856490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
581,NCT02849847,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
582,NCT02842970,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
583,NCT02841397,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
584,NCT02833571,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
585,NCT02811328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
586,NCT02810080,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
587,NCT02805933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
588,NCT02805777,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
589,NCT02800057,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
590,NCT02799342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
591,NCT02799329,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
592,NCT02795689,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
593,NCT02787343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
594,NCT02784431,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
595,NCT02771119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
596,NCT02764580,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
597,NCT02761759,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
598,NCT02756260,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
599,NCT02746289,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
600,NCT02746120,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
601,NCT02719444,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
602,NCT02716155,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
603,NCT02712931,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
604,NCT02711254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
605,NCT02699021,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
606,NCT02698787,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
607,NCT02698397,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
608,NCT02697604,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
609,NCT02686450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
610,NCT02684110,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
611,NCT02680964,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
612,NCT02680860,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
613,NCT02662049,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
614,NCT02638883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
615,NCT02634996,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
616,NCT02634554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
617,NCT02634125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
618,NCT02631213,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
619,NCT02626624,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
620,NCT02624739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
621,NCT02622919,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
622,NCT02599519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
623,NCT02597296,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
624,NCT02596464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
625,NCT02579486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
626,NCT02576210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
627,NCT02561052,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
628,NCT02553395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
629,NCT02548429,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
630,NCT02543814,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
631,NCT02540577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
632,NCT02540564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
633,NCT02535234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
634,NCT02525783,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
635,NCT02517645,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
636,NCT02506400,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
637,NCT02495116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
638,NCT02480829,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
639,NCT02474784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
640,NCT02474771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
641,NCT02474758,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
642,NCT02458378,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
643,NCT02455063,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
644,NCT02441634,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
645,NCT02436005,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
646,NCT02430441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
647,NCT02405871,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
648,NCT02403167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
649,NCT02396914,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
650,NCT02388425,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
651,NCT02383082,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
652,NCT02380716,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
653,NCT02380014,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
654,NCT02365545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
655,NCT02365467,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
656,NCT02364375,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
657,NCT02353377,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
658,NCT02343068,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
659,NCT02340832,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
660,NCT02327598,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
661,NCT02325609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
662,NCT02322840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
663,NCT02312141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
664,NCT02300974,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
665,NCT02289534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
666,NCT02284321,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
667,NCT02283125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
668,NCT02280577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
669,NCT02275624,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
670,NCT02272114,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
671,NCT02271087,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
672,NCT02268227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
673,NCT02255539,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
674,NCT02239263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
675,NCT02231034,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
676,NCT02223663,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
677,NCT02218450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
678,NCT02195362,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
679,NCT02195128,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
680,NCT02191800,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
681,NCT02187458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
682,NCT02167880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
683,NCT02166073,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
684,NCT02142465,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
685,NCT02142374,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
686,NCT02142023,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
687,NCT02141334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
688,NCT02134236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
689,NCT02124538,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
690,NCT02108275,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
691,NCT02089646,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
692,NCT02086812,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
693,NCT02085174,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
694,NCT02082847,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
695,NCT02070601,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
696,NCT02036385,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
697,NCT02020447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
698,NCT02006251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
699,NCT02004249,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
700,NCT02003105,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
701,NCT01989390,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
702,NCT01989377,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
703,NCT01988727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
704,NCT01988025,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
705,NCT01984151,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
706,NCT01973621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
707,NCT01966211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
708,NCT01957982,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
709,NCT01951131,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
710,NCT01950767,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
711,NCT01940458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
712,NCT01940211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
713,NCT01937000,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
714,NCT01936987,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
715,NCT01916083,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
716,NCT01906736,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
717,NCT01905241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
718,NCT01896141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
719,NCT01894698,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
720,NCT01883557,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
721,NCT01882309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
722,NCT01877369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
723,NCT01874925,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
724,NCT01867008,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
725,NCT01859975,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
726,NCT01854879,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
727,NCT01847846,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
728,NCT01835769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
729,NCT01835366,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
730,NCT01827488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
731,NCT01820741,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
732,NCT01801995,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
733,NCT01801241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
734,NCT01795807,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
735,NCT01795118,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
736,NCT01792869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
737,NCT01790867,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
738,NCT01787981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
739,NCT01777880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
740,NCT01773941,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
741,NCT01773265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
742,NCT01747265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
743,NCT01738230,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
744,NCT01738165,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
745,NCT01733264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
746,NCT01733251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
747,NCT01724541,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
748,NCT01721122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
749,NCT01715454,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
750,NCT01700764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
751,NCT01697813,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
752,NCT01697774,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
753,NCT01674400,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
754,NCT01670006,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
755,NCT01662479,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
756,NCT01660113,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
757,NCT01658189,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
758,NCT01652846,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
759,NCT01643200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
760,NCT01640795,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
761,NCT01630707,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
762,NCT01629836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
763,NCT01627405,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
764,NCT01614925,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
765,NCT01613742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
766,NCT01610505,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
767,NCT01610349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
768,NCT01607606,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
769,NCT01604967,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
770,NCT01597271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
771,NCT01591369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
772,NCT01582386,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
773,NCT01575210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
774,NCT01564589,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
775,NCT01560156,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
776,NCT01558609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
777,NCT01556750,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
778,NCT01546831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
779,NCT01546584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
780,NCT01533831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
781,NCT01533103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
782,NCT01532752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
783,NCT01532440,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
784,NCT01524263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
785,NCT01515618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
786,NCT01513512,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
787,NCT01499030,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
788,NCT01494376,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
789,NCT01480570,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
790,NCT01476826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
791,NCT01473134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
792,NCT01470079,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
793,NCT01464580,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
794,NCT01463618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
795,NCT01462955,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
796,NCT01450540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
797,NCT01443299,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
798,NCT01443286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
799,NCT01442389,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
800,NCT01436669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
801,NCT01436461,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
802,NCT01414491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
803,NCT01414270,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
804,NCT01412112,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
805,NCT01408017,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
806,NCT01403584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
807,NCT01392261,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
808,NCT01379794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
809,NCT01374243,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
810,NCT01370785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
811,NCT01367171,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
812,NCT01365689,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
813,NCT01358682,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
814,NCT01336868,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
815,NCT01313351,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
816,NCT01313195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
817,NCT01311726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
818,NCT01307709,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
819,NCT01297751,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
820,NCT01286792,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
821,NCT01258400,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
822,NCT01246115,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
823,NCT01240733,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
824,NCT01239576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
825,NCT01234480,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
826,NCT01230398,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
827,NCT01201889,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
828,NCT01194752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
829,NCT01194739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
830,NCT01194726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
831,NCT01183195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
832,NCT01180257,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
833,NCT01171066,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
834,NCT01166607,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
835,NCT01164527,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
836,NCT01158963,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
837,NCT01150227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
838,NCT01148251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
839,NCT01147094,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
840,NCT01145651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
841,NCT01145378,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
842,NCT01143116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
843,NCT01140919,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
844,NCT01127347,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
845,NCT01112475,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
846,NCT01108822,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
847,NCT01106222,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
848,NCT01103869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
849,NCT01100983,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
850,NCT01098682,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
851,NCT01097824,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
852,NCT01092871,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
853,NCT01077141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
854,NCT01070992,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
855,NCT01067040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
856,NCT01062464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
857,NCT01062412,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
858,NCT01062217,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
859,NCT01057134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
860,NCT01043497,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
861,NCT01039064,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
862,NCT01037439,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
863,NCT01030588,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
864,NCT01029028,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
865,NCT01022554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
866,NCT01016236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
867,NCT01008202,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
868,NCT01000454,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
869,NCT00993772,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
870,NCT00990483,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
871,NCT00990210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
872,NCT00986908,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
873,NCT00981188,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
874,NCT00979498,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
875,NCT00979030,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
876,NCT00969748,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
877,NCT00968474,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
878,NCT00961519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
879,NCT00960947,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
880,NCT00957632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
881,NCT00957138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
882,NCT00956618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
883,NCT00955331,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
884,NCT00946075,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
885,NCT00944411,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
886,NCT00942942,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
887,NCT00935974,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
888,NCT00932789,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
889,NCT00924716,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
890,NCT00911040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
891,NCT00906958,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
892,NCT00906815,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
893,NCT00906009,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
894,NCT00905749,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
895,NCT00903058,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
896,NCT00901667,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
897,NCT00900705,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
898,NCT00889746,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
899,NCT00878982,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
900,NCT00877916,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
901,NCT00865930,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
902,NCT00865735,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
903,NCT00863486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
904,NCT00863447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
905,NCT00858091,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
906,NCT00850434,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
907,NCT00850109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
908,NCT00846820,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
909,NCT00843752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
910,NCT00840619,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
911,NCT00824018,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
912,NCT00821769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
913,NCT00820040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
914,NCT00819130,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
915,NCT00818922,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
916,NCT00810498,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
917,NCT00810459,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
918,NCT00809406,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
919,NCT00806052,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
920,NCT00802750,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
921,NCT00800891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
922,NCT00799981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
923,NCT00794534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
924,NCT00791414,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
925,NCT00790621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
926,NCT00789334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
927,NCT00788450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
928,NCT00788437,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
929,NCT00782119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
930,NCT00781651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
931,NCT00781222,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
932,NCT00780065,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
933,NCT00779623,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
934,NCT00777283,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
935,NCT00776893,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
936,NCT00776815,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
937,NCT00776152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
938,NCT00773903,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
939,NCT00773721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
940,NCT00769340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
941,NCT00767910,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
942,NCT00766727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
943,NCT00764491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
944,NCT00764452,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
945,NCT00760643,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
946,NCT00759694,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
947,NCT00758979,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
948,NCT00758875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
949,NCT00758095,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
950,NCT00756496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
951,NCT00754598,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
952,NCT00748917,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
953,NCT00748033,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
954,NCT00747266,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
955,NCT00739245,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
956,NCT00732264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
957,NCT00732134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
958,NCT00728702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
959,NCT00727805,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
960,NCT00727688,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
961,NCT00726297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
962,NCT00726024,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
963,NCT00725816,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
964,NCT00725699,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
965,NCT00716313,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
966,NCT00690742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
967,NCT00681057,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
968,NCT00680251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
969,NCT00678808,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
970,NCT00676546,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
971,NCT00676078,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
972,NCT00670137,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
973,NCT00660556,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
974,NCT00659139,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
975,NCT00653211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
976,NCT00639340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
977,NCT00630526,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
978,NCT00617630,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
979,NCT00617162,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
980,NCT00616226,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
981,NCT00615342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
982,NCT00608647,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
983,NCT00597571,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
984,NCT00591513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
985,NCT00589069,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
986,NCT00588601,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
987,NCT00587613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
988,NCT00587509,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
989,NCT00586456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
990,NCT00579176,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
991,NCT00578513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
992,NCT00578487,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
993,NCT00576953,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
994,NCT00561847,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
995,NCT00542477,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
996,NCT00529685,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
997,NCT00506220,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
998,NCT00448812,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
999,NCT00350259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1000,NCT04371159,0,0,0,0,Each participant will test their urine sample using the Velieve U.S. device,Device: Velieve U.S.,Velieve U.S.,Experimental,0,0,0,0,0,0,0,0,0,0,0
1001,NCT04474496,0,0,0,0,Marshallese persons 18 years of age or older residing in the United States,Other: Assessing impact of COVID19,Marshallese in the U.S.,0,0,0,0,0,0,0,0,0,0,0,0
1002,NCT02801266,0,0,0,0,"['The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.', 'The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.']",Behavioral: Evidence informed birth control counseling,"['Intervention', 'No intervention']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1003,NCT01599390,0,0,0,0,0,Other: Data collection,Influenza Group,0,0,0,0,0,0,0,0,0,0,0,0
1004,NCT00312702,0,No,0,No,"['Falciparum Malaria Protein 11 with AS02A adjuvant', 'Falciparum Malaria Protein 11 with AS02A adjuvant']","['Biological: Falciparum Malaria Protein 11 with AS02A adjuvant', 'Biological: Falciparum Malaria Protein 11 with AS02A adjuvant']","['10µg dose FMP011', '50µg dose FMP011']","['Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male', 'Hispanic or Latino', 'Not Hispanic or Latino', 'Unknown or Not Reported', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,United States,"['BG000', 'BG001', 'BG002', 'BG003']","['5', '13', '1', '19']"
1005,NCT00312663,0,No,0,No,"['Falciparum Malaria Protein 11 with AS01B adjuvant', 'Falciparum Malaria Protein 11 with AS01B adjuvant']","['Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.', 'Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.']","['10ug dose FMP011', '50ug dose FMP011']","['Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,United States,"['BG000', 'BG001', 'BG002', 'BG003']","['5', '13', '6', '24']"
1006,NCT01153880,0,0,0,0,"['Age at time of prescription was <9 months', 'Age at time of prescription was uncertain for <9 months', 'Age at time of prescription was 9 months to 6 years', 'Age at time of prescription was 7 to 18 years', 'Age at time of prescription was 19 to 65 years', 'Age at time of prescription was 66 years and older']","['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin', 'Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']","['Age <9 months definitive', 'Age <9 months uncertain', '9 months to 6 years', '7 to 18 years', '19 to 65 years', '66 years and older']",0,0,0,0,0,0,0,0,0,0,0,0
1007,NCT02019732,0,0,0,0,"Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.",Other: Data collection,Study Group,0,0,0,0,0,0,0,0,0,0,0,0
1008,NCT03972358,0,0,0,0,"Mifepristone 200 mg orally on day 1.

Misoprostol 800 mcg buccally on day 2 (24 hours after mifepristone).","['Drug: Mifepristone', 'Drug: Misoprostol']",Medical menstrual regulation,Experimental,0,0,0,0,0,0,0,0,0,0,0
1009,NCT00948233,0,0,0,0,"['Educational video game', 'Pamphlets on stopping tobacco use']","['Behavioral: Video Game', 'Behavioral: Surveys', 'Behavioral: Pamphlet', 'Behavioral: Surveys']","['Intervention', 'Standard Care']",0,0,0,0,0,0,0,0,0,0,0,0
1010,NCT00026728,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1011,NCT01211990,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1012,NCT02663219,0,0,0,0,"['The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.', 'Standard of care']",Behavioral: Intervention,"['Intervention', 'Control']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1013,NCT00121108,0,0,0,0,"['Placebo', 'MEDI-524']","['Other: Placebo', 'Biological: MEDI-524']","['2', '1']","['Placebo Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1014,NCT01861210,0,0,0,0,"['Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.', 'Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention\'s ""Fundamentals of HIV Prevention Counseling"" training.']","['Behavioral: Couples Voluntary HIV Counseling and Testing', 'Behavioral: Individual Counseling and Testing']","['Couples Counseling and Testing', 'Individudal Counseling and Testing']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1015,NCT02911155,0,0,0,0,radiologic technologists certified in nuclear medicine,0,US Nuclear Medicine Technologist,0,0,0,0,0,0,0,0,0,0,0,0
1016,NCT00724867,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['Belimumab 1 mg/kg IV every 28 days', 'Belimumab 10 mg/kg IV every 28 days']","['Biological: Belimumab 1 mg/kg', 'Biological: Belimumab 10 mg/kg']","['Belimumab 1 mg/kg', 'Belimumab 10 mg/kg']","['Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male']",0,0,0,"['Black or African American/African Heritage', 'American Indian or Alaska Native', 'Asian: Central Asian Heritage', 'Asian: East Asian Heritage', 'Asian: Japanese Heritage', 'Asian: South Asian Heritage', 'Asian: Southeast Asian Heritage', 'Native Hawaiian or Other Pacific Islander', 'White: Middle East/North African Heritage', 'White: White/Caucasian/European Heritage', 'Mixed Race']",BG000,268
1017,NCT03973905,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).\n\nThis post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).\n\nThis post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.']","['Other: Not applicable / dataset analysis', 'Other: Not applicable / dataset analysis']","['Pertussis Case Group', 'Control Group']",0,0,0,0,0,"['Female', 'Male']",0,0,0,"[""Infant's age (weeks)"", 'White', 'Black', 'Other-unspecified']","['BG000', 'BG001', 'BG002']","['107', '183', '290']"
1018,NCT00340457,0,0,0,0,"['African American patients with renal cancer from two geographic areas of the US', 'African American participants without renal cancer from two geographic areas of the US']",0,"['Cases', 'Controls']",0,0,0,0,0,0,0,0,0,0,0,0
1019,NCT02429284,0,0,0,0,"Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.",0,Patients newly diagnosed with CTEPH,0,0,0,0,0,0,0,0,0,0,0,0
1020,NCT02889263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1021,NCT03995745,0,0,0,0,"[""Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period."", 'Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.']",Behavioral: Medication adherence and financial incentives,"['adherence based financial incentives', 'control']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1022,NCT00928694,"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['Fenofibrate U.S. Formulation', 'Fenofibrate UK Formulation']","['Drug: fenofibrate (U.S. formulation)', 'Drug: fenofibrate (UK formulation)']","['1', '2']","['Active Comparator', 'Active Comparator']",0,0,0,0,"['Female', 'Male']",0,0,0,0,BG000,14
1023,NCT02153996,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1024,NCT00413673,0,0,0,0,PRK,Procedure: PRK,1,Experimental,0,0,0,0,0,0,0,0,0,0,0
1025,NCT03867409,0,0,0,0,"['Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.', 'Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.', 'Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.', 'Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.']","['Behavioral: message delivered via virtual technology', 'Behavioral: message delivered via virtual technology', 'Behavioral: message delivered via virtual technology', 'Behavioral: message delivered via virtual technology']","['Concordant virtual human', 'Dis-concordant virtual human', 'Concordant text', 'Dis-concordant text']","['Experimental', 'Experimental', 'Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1026,NCT04004260,0,0,0,0,"['The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.', 'The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.']","['Behavioral: Internet-based Cognitive Behavior Therapy', 'Behavioral: Internet-based Cognitive Behavior Therapy']","['Experimental group', 'Weekly check-in control group']","['Experimental', 'Other']",0,0,0,0,0,0,0,0,0,0,0
1027,NCT04205877,0,0,0,0,All participants will have the same data collected at the same time points.,Device: Transcatheter PDA Closure,Registry Group,0,0,0,0,0,0,0,0,0,0,0,0
1028,NCT01262079,0,0,0,0,0,0,"['Group 1: 6-15 years old', 'Group 2: 16-25 years old', 'Group 3: 26-35 years old', 'Group 4: 36-45 years old', 'Group 5: 46-55 years old', 'Group 6: 56-65 years old', 'Group 7: 66-75 years old', 'Group 8: 76-85 years old', 'Group 9: > 85 years old']",0,0,0,0,0,0,0,0,0,0,0,0
1029,NCT00646438,0,0,0,0,"['strict glucose control (study arm)', 'standard insulin treatment (control arm)']",Drug: Strict Glycemic Control for one year post-op CABG,"['1', '2']","['Active Comparator', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1030,NCT00341588,0,0,0,0,"['Male U.S. serviceman, age 18-45 years old with TGCT', 'Male U.S. serviceman, age 18-45 years old without TGCT']",0,"['Cases', 'Controls']",0,0,0,0,0,0,0,0,0,0,0,0
1031,NCT04562636,0,0,0,0,"['Four environmental messages from the Meatless Monday campaign.', 'Four health messages from the Meatless Monday campaign.', ""Four neutral messages about checking one's credit score.""]","['Other: Environmental message', 'Other: Health message', 'Other: Neutral Message']","['Environment-focused Meatless Monday messages', 'Health-focused Meatless Monday messages', 'Neutral Message']","['Experimental', 'Experimental', 'Other']",0,0,0,0,0,0,0,0,0,0,0
1032,NCT03924505,0,0,0,0,"['This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.', 'This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.']","['Behavioral: Implementation Manual with External Facilitation Intervention', 'Behavioral: Implementation Manual only']","['Implementation Manual and External Facilitation', 'Implementation Manual - only']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1033,NCT02334462,0,0,0,0,"['Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530', 'Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.', 'Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530', 'Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.', 'Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530', 'Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.', 'Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530']","['Biological: Pfs25M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel', 'Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel', 'Drug: TWINRIX', 'Drug: Menactra']","['Group 1- Mali', 'Group 1-U.S', 'Group 2- Mali', 'Group 2-U.S', 'Group 3- Mali', 'Group 3- U.S.', 'Group 4- Mali']","['Experimental', 'Experimental', 'Experimental', 'Experimental', 'Experimental', 'Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1034,NCT03311295,0,0,0,0,0,Device: ARTO System,ARTO System,Experimental,0,0,0,0,0,0,0,0,0,0,0
1035,NCT03242278,0,0,0,0,"['NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)', 'NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)']","['Drug: Rivaroxaban (Xarelto, BAY59-7939)', 'Drug: Rivaroxaban (Xarelto, BAY59-7939)']","['NVAF patients receiving 20 mg rivaroxaban', 'NVAF patients receiving 15 mg rivaroxaban']",0,0,0,0,0,0,0,0,0,0,0,0
1036,NCT03683134,0,0,0,0,"['Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.', 'Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.']","['Behavioral: Mediterranean diet', 'Dietary Supplement: Olive oil and mixed nuts', 'Behavioral: American Heart Association']","['Mediterranean diet group', 'American Heart Association group']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1037,NCT04047316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1038,NCT03952364,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1039,NCT04021030,0,0,0,0,0,Behavioral: Cognitive Behavioral Therapy (CBT),Cognitive Behavioral Therapy (CBT),Experimental,0,0,0,0,0,0,0,0,0,0,0
1040,NCT02959827,0,No,OTHER,Yes,"Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent",Drug: Iodinated contrast agents,Iodinated contrast agents,0,0,0,0,0,"['<1 month', '1 to 3 months', '3 to 6 months', '6 months to 1 year', '1 to 4 years', 'Female', 'Male', 'White', 'African American', 'Hispanic', 'Asian/Pacific islander', 'Other or missing']",0,0,0,0,BG000,2320
1041,NCT02395536,0,No,0,Yes,"['Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.', 'Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.']","['Other: office setting', 'Other: hosptial setting']","['In office Outside walls of hospital', 'Traditional Hospital Setting']","['Experimental', 'Other']",0,0,0,0,"['Female', 'Male']","['BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002']","['251', '231', '482', '251', '231', '482', '0', '0', '0', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482', '251', '231', '482']","['Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants', 'Participants']",United States,"['BG000', 'BG001', 'BG002']","['251', '231', '482']"
1042,NCT03628235,0,0,0,0,"['CAG length ≥ 40; DCL = 4, TFC ≥ 11', 'CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10', 'CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6']","['Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey', 'Behavioral: Online survey']","['Early stage HDGECs', 'Middle stage HDGECs', 'Late stage HDGECs', 'Companions of early stage HDGECs', 'Companions of middle stage HDGECs', 'Companions of late stage HDGECs']",0,0,0,0,0,0,0,0,0,0,0,0
1043,NCT02787538,0,0,0,0,"[""The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option."", 'The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.']","['Behavioral: US-ANSWER-2 decision aid', 'Behavioral: Control group (Online medication guide)']","['US-ANSWER-2 decision aid', 'Control group (Online medication guide)']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1044,NCT01290393,0,0,0,0,"['Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.', 'Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.']","['Other: Data collection', 'Other: Data collection']","['Exposed vaccinated cohort', 'Non-exposed vaccinated cohort']",0,0,0,0,0,0,0,0,0,0,0,0
1045,NCT04263311,0,0,0,0,"['There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.', 'There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes']",Behavioral: CHW,"['Community Health Workers (CHW) treatment group', 'Control group']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1046,NCT00875641,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",No,OTHER,Yes,"['HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.']","['Other: Health Insurance Database', 'Other: Health Insurance Database', 'Other: Health Insurance Database']","['HRV cohort', 'Concurrent Control cohort', 'Recent Historical Control cohort']",0,0,0,0,0,"['Female', 'Male', 'Northeast', 'South/Southeast', 'Midwest', 'West']",0,0,0,US Geographic Region,"['BG000', 'BG001', 'BG002', 'BG003']","['57931', '173384', '159344', '390659']"
1047,NCT03199846,0,0,0,0,"['Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma', 'Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.', 'Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.', 'Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.', 'Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016', 'Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016']","['Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional', 'Other: Non-Interventional']","['advanced melanoma patients', 'Ipi monotherapy', 'Ipi + nivo combination therapy', 'Dabrafenib + trametinib combination therapy', 'Pembro monotherapy', 'Nivo monotherapy']",0,0,0,0,0,0,0,0,0,0,0,0
1048,NCT04587245,0,0,0,0,Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients,Other: Online questionnaire and interviews,Physicians,0,0,0,0,0,0,0,0,0,0,0,0
1049,NCT02773979,0,0,0,0,"['Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1', 'CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1', 'CQ/PfSPZ Challenge 102400 sporozoites N=9']","['Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge', 'Other: Placebo', 'Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge', 'Other: Placebo', 'Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge']","['Group 1: PfSPZ 51200 sporozoites/Placebo', 'Group 2: PfSPZ 102400 sporozoites/Placebo', 'Group 3: PfSPZ 102400 sporozoites']","['Active Comparator', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1050,NCT03274726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1051,NCT01283828,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1052,NCT04191824,0,0,0,0,"['Immediate return of results to inform participant of APOL1 status (either positive or negative).', 'Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.']","['Diagnostic Test: APOL1 status', 'Diagnostic Test: APOL1 status']","['Immediate Return of Results', 'Delayed Return of Results']","['Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1053,NCT03197688,0,0,0,0,Not applicable as non-interventional study,Other: Notapplicable,Notapplicable,0,0,0,0,0,0,0,0,0,0,0,0
1054,NCT02813577,"Prior to PI publication of site results, sponsor requires publication of multi-centers results.",No,OTHER,Yes,This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.,Device: Lutonix® 035 Drug Coated Balloon PTA Catheter,Lutonix® 035 Drug Coated Balloon PTA Catheter,Other,0,0,0,0,"['Female', 'Male', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,"['≥18 years of age', 'United States']",BG000,4
1055,NCT00666380,0,0,0,0,0,"['Biological: Plasmodium falciparum Malaria Protein 010 (FMP010)', 'Biological: Plasmodium falciparum Malaria Protein 010 (FMP010)']","['10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant', '50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1056,NCT01287247,0,0,0,0,"['The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.', 'The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.']","['Biological: Xeomin®', 'Biological: Xeomin®']","['Cervical Dystonia', 'Blepharospasm']",0,0,0,0,0,0,0,0,0,0,0,0
1057,NCT04163341,0,0,0,0,0,Behavioral: Adapted Common Elements Treatment Approach,"['CETA protocol', 'Enhanced Usual Care']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1058,NCT02987335,0,0,0,0,"['N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.', 'N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp', 'N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp', 'N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp']","['Drug: Pancreatic Clamp', 'Drug: Pancreatic Clamp', 'Drug: Pancreatic Clamp', 'Drug: Pancreatic Clamp']","['Lean Diabetes Subjects', 'Type 2 Diabetes Mellitus Subjects', 'Type 1 Diabetes Mellitus Subjects', 'Nondiabetic Subjects']",0,0,0,0,0,0,0,0,0,0,0,0
1059,NCT02867722,0,0,0,0,Patients will receive daylight-PDT treatment (aminolevulinic acid),Drug: aminolevulinic acid HCl,Daylight PDT,Experimental,0,0,0,0,0,0,0,0,0,0,0
1060,NCT03276637,0,0,0,0,"Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.",Genetic: Whole exome sequencing,Healthy Active-Duty Airmen Cohort,Experimental,0,0,0,0,0,0,0,0,0,0,0
1061,NCT03192891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1062,NCT03373045,0,0,0,0,"To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.",0,Cohort of US adults with severe asthma,0,0,0,0,0,0,0,0,0,0,0,0
1063,NCT04229212,0,0,0,0,"['No drainage', 'a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed']","Device: hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)","['No drainage', 'Drainage']","['No Intervention', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1064,NCT02848781,0,0,0,0,"['Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.', 'Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.', 'The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.']","['Device: Implantable Cardioverter Defibrillator (ICD)', 'Procedure: Catheter Ablation', 'Device: Implantable Cardioverter Defibrillator (ICD)', 'Procedure: Catheter Ablation']","['ICD with Ablation', 'ICD Only', 'Ablation Only (Registry)']","['Experimental', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1065,NCT00385047,0,0,0,0,"['FMP 2.1 50 μg FMP2.1/AS01B', 'FMP 2.1 50 μg FMP2.1/AS02A']","['Biological: Group A FMP2.1/AS01B', 'Biological: Group B FMP2.1/AS02A']","['Group A', 'Group B']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1066,NCT02993120,0,0,0,0,"['For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.', '• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.', 'For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks']",0,"['Cohort 1', 'Cohort 2', 'Cohort 3']",0,0,0,0,0,0,0,0,0,0,0,0
1067,NCT03045120,0,0,0,0,"['Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.', 'Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.', 'Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.', 'Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.']",0,"['dasatinib cohort', 'imatinib cohort', 'nilotinib cohort', 'bosutinib cohort']",0,0,0,0,0,0,0,0,0,0,0,0
1068,NCT01154296,0,No,0,No,"['Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.', 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.']",Behavioral: RESPECT-2 Counseling,"['Rapid HIV Testing w/ Counseling (Group 1)', 'Rapid HIV Testing & Information Only (Group 2)']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,"['<25 years', '>=25 years', 'Male sex', 'Female sex', 'Black', 'Hispanic', 'White', 'Other', 'United States']","['BG000', 'BG001', 'BG002']","['2505', '2507', '5012']"
1069,NCT02857764,0,0,0,0,"['Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.', 'Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.', 'Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.', 'Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.', 'Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.']",0,"['Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users', 'Canagliflozin New Users', 'Dapagliflozin New Users', 'Empagliflozin New Users', 'First-time Non-SGLT2i AHA New Users']",0,0,0,0,0,0,0,0,0,0,0,0
1070,NCT00412568,0,0,0,0,PRK control group,Procedure: Photorefractive Keratectomy (PRK),1,Active Comparator,0,0,0,0,0,0,0,0,0,0,0
1071,NCT03353480,0,0,0,0,"['250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US', '250mg Azithromycin tablet manufactured at Pfizer Dalian, China']","['Drug: Azithromycin Tablet manufactured in US', 'Drug: Azithromycin Tablet manufactured in China']","['Reference', 'Experimental']","['Other', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1072,NCT00800267,0,0,0,0,0,"['Drug: fixed combination latanoprost-timolol', 'Drug: latanoprost 0.005%', 'Drug: timolol 0.5%']","['Fixed combination of latanoprost 0.005% and timolol 0.5%', 'latanoprost 0.005%', 'Timolol - 0.5%']","['Experimental', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1073,NCT00601835,"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.",No,OTHER,Yes,"['Participants received Canadian manufactured Td vaccine', 'Participants received US manufactured Td vaccine']","['Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine', 'Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine']","['Canadian Td Vaccine Group', 'United States Td Vaccine Group']","['Experimental', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002']","['2950', '700', '3650']"
1074,NCT01087905,0,No,0,No,"['Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks', 'Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks', 'Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks\n\n2 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks\n\n2 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks', 'Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks', 'Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks\n\n6 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks\n\n6 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.']","['Drug: Nicotine patch', 'Drug: Nicotine patch', 'Behavioral: CMAC', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Behavioral: CMAC', 'Drug: Nicotine patch', 'Drug: Nicotine patch', 'Behavioral: CMAC', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Drug: Nicotine patch', 'Drug: Nicotine gum', 'Behavioral: CMAC']","['2 Weeks of Nicotine Patch Only, No CMAC', '2 Weeks of Nicotine Patch Only plus CMAC', '2 Wks Nicotine Patch+Nic Gum, No CMAC', '2 Wks Nicotine Patch+Nic Gum plus CMAC', '6 Weeks of Nicotine Patch Only, No CMAC', '6 Weeks of Nicotine Patch Only plus CMAC', '6 Wks Nicotine Patch+Nic Gum, No CMAC', '6 Wks Nicotine Patch+Nic Gum plus CMAC']","['Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002', 'BG003', 'BG004', 'BG005', 'BG006', 'BG007', 'BG008']","['119', '126', '123', '122', '122', '127', '121', '127', '987']"
1075,NCT02616198,0,0,0,0,"['EquiaFil G-coat combination was applied on one randomly selected cavity to be restored', 'EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored', 'River SC G-coat combination was applied on one randomly selected cavity to be restored', 'River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored']","['Other: EquiaFil Fuji Varnish', 'Other: Riva SC G-coat', 'Other: Riva SC Fuji Varnish', 'Other: EquiaFil G-coat', 'Other: Riva SC G-coat', 'Other: Riva SC Fuji Varnish', 'Other: EquiaFil G-coat', 'Other: EquiaFil Fuji Varnish', 'Other: Riva SC Fuji Varnish', 'Other: EquiaFil G-coat', 'Other: EquiaFil Fuji Varnish', 'Other: Riva SC G-coat']","['EquiaFil G-coat', 'EquiaFil Fuji Varnish', 'Riva SC G-coat', 'Riva SC Fuji Varnish']","['Active Comparator', 'Active Comparator', 'Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1076,NCT00007540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1077,NCT02163525,0,0,0,0,"['Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)', 'Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)']","['Procedure: Global Fibroid Ablation (GFA)', 'Procedure: Uterine Artery Embolization (UAE)', 'Procedure: Global Fibroid Ablation (GFA)', 'Procedure: Abdominal or Laparoscopic Myomectomy']","['Ablation vs Embolization', 'Ablation vs Myomectomy']","['Active Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1078,NCT03310112,0,0,0,0,"['Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.', 'Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.', 'Participants will receive no intervention but will be tested before and after a no-training interval.']","['Behavioral: 4-week MBAT', 'Behavioral: 2-week MBAT']","['4-week MBAT', '2-week MBAT', 'No training control (NTC)']","['Experimental', 'Active Comparator', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1079,NCT02766634,0,0,0,0,0,"['Biological: Filgrastim Hospira (US)', 'Biological: U.S.-approved Neupogen®', 'Biological: Filgrastim Hospira (US)', 'Biological: U.S.-approved Neupogen®']","['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1080,NCT02971709,0,0,0,0,"['Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.', 'Passive recreation areas in public parks that remained unshaded at pretest and posttest.']",Behavioral: Shade Sail,"['Shade Sail', 'Unshaded Control']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1081,NCT03801928,0,0,0,0,"['Group treated with Inflectra for Ulcerative Colitis', ""Group treated with Inflectra for Crohn's Disease""]","['Drug: Inflectra', 'Drug: Inflectra']","['Ulcerative Colitis', ""Crohn's Disease""]",0,0,0,0,0,0,0,0,0,0,0,0
1082,NCT01641029,0,0,0,0,"Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.",Other: No intervention,pyelonephritis,0,0,0,0,0,0,0,0,0,0,0,0
1083,NCT02128542,"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:

The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years",No,OTHER,Yes,Participants will receive sofosbuvir+RBV for 12 weeks.,"['Drug: Sofosbuvir', 'Drug: RBV']",Sofosbuvir+RBV 12 weeks,Experimental,0,0,0,0,"['Female', 'Male']",0,0,0,"['Black or African American', 'White', 'Hawaiian or Pacific Islander', 'Other', 'United States', 'CC', 'CT', 'TT', '< 800,000 IU/mL', '≥ 800,000 IU/mL', 'Genotype 2', 'Genotype 2b', 'Genotype 2a/2c', 'No', 'Yes']","['BG000', 'BG001', 'BG002']","['47', '19', '66']"
1084,NCT00573976,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1085,NCT00306007,0,0,0,0,"['English speaking women recruited from the general OB/GYN clinic', 'Spanish speaking (monolingual) women recruited from the general OB/GYN clinic', 'English speaking women recruited from the abortion clinic', 'Spanish speaking (monolingual) women recruited from the abortion clinic']",0,"['English prenatal', 'Spanish prenatal', 'English abortion clinic', 'Spanish abortion clinic']",0,0,0,0,0,0,0,0,0,0,0,0
1086,NCT02766647,0,0,0,0,0,"['Biological: Filgrastim Hospira (US)', 'Biological: US-approved Neupogen®', 'Biological: Filgrastim Hospira (US)', 'Biological: US-approved Neupogen®']","['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1087,NCT04460898,0,0,0,0,HR+/HER2- metastatic breast cancer patients in the US.,0,Breast Cancer Patients,0,0,0,0,0,0,0,0,0,0,0,0
1088,NCT00413517,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1089,NCT02882100,0,0,0,0,"['NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents', 'NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents']","['Biological: adjuvanted trivalent influenza vaccine', 'Biological: trivalent influenza vaccine', 'Biological: trivalent influenza vaccine']","['aTIV', 'TIV']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1090,NCT00533975,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1091,NCT02109757,0,0,0,0,"['This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.', 'This group will not receive software intervention prior to and after one-on-one education, only afterwards.']","['Other: Software intervention and education', 'Other: Education only']","['Software intervention and education', 'Education only']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1092,NCT00959933,0,0,0,0,"['Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)', 'Rebetol 200 Capsules (Schering Corporation, U.S.A.)']","['Drug: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)', 'Drug: Rebetol 200 Capsules (Schering Corporation, U.S.A.)']","['1', '2']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1093,NCT00960479,0,0,0,0,"['Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)', 'Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)']","['Drug: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)', 'Drug: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)']","['1', '2']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1094,NCT03266497,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1095,NCT02207569,0,No,0,No,"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:

Evolut R Transcatheter Aortic Valve (TAV)
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
EnVeo R Loading System (LS)",Device: CoreValve Evolut R TAVR system,CoreValve Evolut R TAVR system,Experimental,0,0,0,0,"['Female', 'Male']",0,0,0,United States,BG000,241
1096,NCT02569632,0,0,0,0,Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals),Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals),Open Label: MenB-FHbp,Experimental,0,0,0,0,0,0,0,0,0,0,0
1097,NCT02069925,0,0,0,0,"['This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis', 'This intervention will provide equivalent best practice care without the benefit of an early detection campaign']","['Behavioral: Early Detection (ED)', 'Behavioral: Usual Detection', 'Behavioral: Usual Detection']","['Early Detection (ED)', 'Usual Detection']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1098,NCT03433131,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1099,NCT02746809,0,No,0,No,Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.,Device: CoreValve Evolut 34R TAVR system,CoreValve Evolut 34R TAVR system,Experimental,0,0,0,0,"['Female', 'Male']","['BG000', 'BG000', 'BG000', 'BG000']","['60', '60', '0', '60']","['Participants', 'Participants', 'Participants', 'Participants']",United States,BG000,60
1100,NCT00328380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1101,NCT04552535,0,0,0,0,"['Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))', 'Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))']","['Drug: Second line (2L) afatinib', 'Drug: Second line chemotherapy']","['Second line (2L) afatinib', 'Second line (2L) chemotherapy']",0,0,0,0,0,0,0,0,0,0,0,0
1102,NCT03293875,0,0,0,0,"['Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.', 'Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.']","['Behavioral: Encuentro', 'Behavioral: Encuentro']","['HIV testing promoted by members of the social network', 'Peer network behavioral intervention']","['Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
1103,NCT01235260,0,0,0,0,"['Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)', 'Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)']","['Drug: Becaplermin users', 'Other: Becaplermin nonusers']","['001', '002']",0,0,0,0,0,0,0,0,0,0,0,0
1104,NCT03390660,0,0,0,0,"born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014",Other: WIC program participation,birth cohorts,0,0,0,0,0,0,0,0,0,0,0,0
1105,NCT00837499,0,0,0,0,0,"['Behavioral: Questionnaire', 'Behavioral: Questionnaire', 'Behavioral: Questionnaire']","['Mexican Women from Mexico', 'Mexican-American Women in U.S.', 'African-American Women in U.S.']",0,0,0,0,0,0,0,0,0,0,0,0
1106,NCT01629537,0,0,0,0,"['Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.', 'Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.']","['Procedure: Placebo Procedure', 'Procedure: Stellate Ganglion Block injection with ropivicane']","['Placebo', 'Stellate Ganglion Block (SGB)']","['Other', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1107,NCT00351741,0,Yes,0,No,"['Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation', 'Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation']","['Device: Ventilation - High Frequency Percussive Ventilation', 'Device: Ventilation - ARDSnet']","['High Frequency', 'Conventional']","['Experimental', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002']","['31', '31', '62']"
1108,NCT01965561,0,Yes,0,0,"['Use of Combat Ready Clamp (CRoC)', 'Use of Abdominal Aortic and Junctional Tourniquet', 'Junctional Emergency Treatment Tool', 'SAM Junctional Tourniquet']","['Device: CRoC', 'Device: AAJT', 'Device: JETT', 'Device: SJT']","['CRoC', 'AAJT', 'JETT', 'SJT']","['Experimental', 'Experimental', 'Experimental', 'Experimental']",0,0,0,0,"['Female', 'Male']",0,0,0,0,BG000,10
1109,NCT01927835,0,0,0,0,"['Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.', 'Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.']","['Biological: DNA-HIV-PT123 vaccine', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: Placebo for DNA/NYVAC/AIDSVAX', 'Biological: DNA-HIV-PT123 vaccine', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: Placebo for DNA/NYVAC/AIDSVAX', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: NYVAC-HIV-PT1 vaccine', 'Biological: NYVAC-HIV-PT4 vaccine', 'Biological: AIDSVAX B/E vaccine', 'Biological: Placebo for DNA/NYVAC/AIDSVAX', 'Biological: Placebo for DNA/NYVAC/AIDSVAX']","['Group 1A: Treatment', 'Group 1B: Treatment', 'Group 2A: Treatment', 'Group 2B: Treatment', 'Group 3A: Placebo', 'Group 3B: Placebo']","['Experimental', 'Experimental', 'Experimental', 'Experimental', 'Placebo Comparator', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
1110,NCT01704235,0,0,0,0,medical physicians and nurse practitioners,Other: Demographic Form and Semi-Structured Interview Guide,Primary health care providers,0,0,0,0,0,0,0,0,0,0,0,0
1111,NCT01306266,0,0,0,0,"['initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo', 'Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg']","['Drug: Rizatriptan', 'Drug: Placebo']","['rizatriptan', 'Placebo']","['Active Comparator', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
1112,NCT00796315,"The Investigator and Sub-Investigators agree that all data, calculations, interpretations, opinions, and recommendations regarding the study will be the property of the Sponsor. The Investigator agrees to consider the results as information subject to confidentiality and use restrictions.",No,OTHER,Yes,Doxylamine Succinate United States Pharmacopeia (USP),Drug: Doxylamine Succinate USP,Doxylamine Succinate (USP),Experimental,0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years']",0,0,0,"['Subjects Aged 2-5 years', 'Subjects Aged 6-11 years', 'Subjects Aged 12-17 years', 'Male, Ages 2-5', 'Female, Ages 2-5', 'Male, Ages 6-11', 'Female, Ages 6-11', 'Male, Ages 12-17', 'Female, Ages 12-17', 'United States']",BG000,41
1113,NCT00005463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1114,NCT03382418,0,0,0,0,"['Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.', 'Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.', 'Participants will receive placebo at Day 0 and Months 2 and 6.']","['Biological: gp145 C.6980 Vaccine', 'Biological: Aluminum Hydroxide Adjuvant', 'Biological: gp145 C.6980 Vaccine', 'Biological: Aluminum Hydroxide Adjuvant', 'Biological: Placebo']","['Group 1: gp145 C.6980 (high dose)', 'Group 2: gp145 C.6980 (low dose)', 'Group 3: Placebo']","['Experimental', 'Experimental', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
1115,NCT00054743,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1116,NCT00730964,0,No,0,No,Open Label,"Drug: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)",Phase 4,Other,0,0,0,0,"['Female', 'Male']",0,0,0,"['<=65 years', 'Between 65 and 75 years', '>=75 years', 'United States']",BG000,1039
1117,NCT02886689,0,0,0,0,"['patients will be those receiving any biotherapy', 'patients will be those not receiving biotherapy : non indication, refusal, contraindication.']",Drug: TNF-alpha antagonist and other biotherapy,"['1', '2']",0,0,0,0,0,0,0,0,0,0,0,0
1118,NCT00005455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1119,NCT01150695,0,0,0,0,"['Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.', 'Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.']","['Other: Placebo', 'Biological: Undiluted Francisella tularensis live attenuated vaccine', 'Other: Placebo', 'Biological: Undiluted Francisella tularensis live attenuated vaccine']","['Group A (DVC-LVS)', 'Group B (USAMRIID-LVS)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1120,NCT00245076,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1121,NCT00935623,0,0,0,0,"['The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).', 'If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.']","['Biological: Malaria Challenge', 'Biological: Malaria Challenge']","['Cohort 1', 'Cohort 2']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1122,NCT03688126,0,0,0,0,"['Lifestyle modification program that is developed by the participant to meet his/her specific needs.', 'Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.']","['Behavioral: Self-Guided Lifestyle Intervention', 'Behavioral: Structured Lifestyle Intervention']","['Self-Guided Lifestyle Intervention', 'Structured Lifestyle Intervention']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1123,NCT02053506,0,0,0,0,"['This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.', 'This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).']","['Dietary Supplement: Immune-enhancing nutritional beverage', 'Dietary Supplement: Placebo (for nutritional beverage and probiotic)', 'Dietary Supplement: Probiotics (BB-12)', 'Dietary Supplement: Placebo (for nutritional beverage and probiotic)']","['Immune-enhancing nutritional beverage', 'Probiotics (BB-12)']","['Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1124,NCT03933215,0,0,0,0,"No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any injectable DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.",Drug: Cladribine Tablets,Cladribine Tablets,0,0,0,0,0,0,0,0,0,0,0,0
1125,NCT03933202,0,0,0,0,"No intervention will be administered as a part of this study. Participants who had decided prior to enrollment to transition from any oral or infusion DMD to treatment with cladribine tablets under routine clinical care and who meet all eligibility criteria will receive an initial treatment course with cladribine tablets in Year 1 and are planned to receive a second course in Year 2, as per the approved United States Prescribing Information (USPI). Data sources for this study will include data extracts from participants' medical records performed by site personnel as well as questionnaires directly filled out by participants.",Drug: Cladribine Tablets,Cladribine Tablets,0,0,0,0,0,0,0,0,0,0,0,0
1126,NCT00005171,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1127,NCT01256164,Investigators were part of the primary publication. Each investigator may publish on the data from subjects enrolled at their site after the initial publication has been submitted.,No,OTHER,Yes,"['After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.', 'Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.']","['Device: Fibrocaps (fibrin sealant)', 'Device: Gelfoam']","['Fibrocaps + Gelfoam', 'Gelfoam']","['Experimental', 'Active Comparator']",0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,"['BG000', 'BG001', 'BG002']","['47', '23', '70']"
1128,NCT03631472,0,0,0,0,"RheOx Treatment (i.e., Bronchial Rheoplasty)",Device: RheOx,RheOx Treatment,Experimental,0,0,0,0,0,0,0,0,0,0,0
1129,NCT03699709,0,0,0,0,0,"Behavioral: Budgeting, purchasing and cooking educational intervention","['Intervention Arm', 'Control Arm']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1130,NCT00237263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1131,NCT02939131,0,No,0,No,"['Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention', 'Enhanced Standard of Care (ESC)']","['Behavioral: Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm', 'Behavioral: Enhanced Standard of Care']","['COMB-R', 'Enhanced Standard of Care']","['Experimental', 'Active Comparator']",0,0,0,0,"['12-18 yrs', '19-24 yrs', 'Female', 'Male', 'White, non-Hispanic', 'Black, Non- Hispanic', 'Hispanic, regardless of race', 'Asian, Pacific Islander', 'More than one race', 'Missing/Unknown', 'Perinatal', 'Behavioral', 'not taking medications', 'taking psychiatric medications']",0,0,0,"['Age, categorized', 'Race/Ethnicity', 'United States']","['BG000', 'BG001', 'BG002', 'BG000', 'BG001', 'BG002']","['81', '75', '156', '6', '7', '13']"
1132,NCT03488264,0,0,0,0,"['50 participants will be recruited from the United States.', '50 participants will be recruited from Jamaica.']",0,"['United States', 'Jamaica']",0,0,0,0,0,0,0,0,0,0,0,0
1133,NCT01873482,0,0,0,0,Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.,Behavioral: Movement to rhythm,Movement with rhythm,Experimental,0,0,0,0,0,0,0,0,0,0,0
1134,NCT02829073,0,0,0,0,"['Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.', 'Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.']","['Device: Neuromonics Tinnitus Treatment Program', 'Device: Placebo Device']","['Oasis™ device', 'Placebo device']","['Experimental', 'Placebo Comparator']",0,0,0,0,0,0,0,0,0,0,0
1135,NCT01369030,0,No,0,No,Subjects with depression who have been prescribed Deplin® daily.,Other: Deplin®,Deplin®,0,0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years']",0,0,0,"['Female', 'Male', 'United States']",BG000,554
1136,NCT01568424,0,No,OTHER,Yes,Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.,Device: CentriMag RVAS placement,Treatment Group,Other,0,0,0,0,"['Female', 'Male']",0,0,0,0,BG000,25
1137,NCT02406599,0,0,0,0,"['The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.', 'The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.']","['Device: Margin Probe', 'Other: Control: Additional inspection']","['SOC + Device', 'SOC + Additional Inspection']","['Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
1138,NCT03965195,0,0,0,0,"['Nursing homes randomized to receive quadrivalent recombinant influenza vaccine (Flublok) for the residents and staff', 'Nursing homes randomized to receive standard dose quadrivalent influenza vaccine for the residents and staff']","['Biological: Recombinant Influenza Vaccine', 'Biological: Standard Dose Quadrivalent Influenza Vaccine']","['RIV4', 'IV4']","['Experimental', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1139,NCT01368549,0,0,0,0,Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.,Other: Metanx® (a medical food),Metanx®,0,0,0,0,0,0,0,0,0,0,0,0
1140,NCT01370954,0,0,0,0,Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.,Other: CerefolinNAC®,CerefolinNAC®,0,0,0,0,0,0,0,0,0,0,0,0
1141,NCT01339546,0,0,0,0,"All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study",Other: no intervention,Study population,0,0,0,0,0,0,0,0,0,0,0,0
1142,NCT02252159,0,0,0,0,"['Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:\n\nWatchful waiting (with or without aspirin)*, or\nPhlebotomy (PHL) alone (with or without aspirin)* - or\nHU alone (without concomitant PHL, with or without aspirin).\n\n(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)', ""Patients with clinically overt PV, with one or more of the following disease characteristics:\n\nTreatment with HU and PHL in combination or\nTreatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or\nA history of thrombosis (venous or arterial) or\nA history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or\nPresence of documented splenomegaly (clinically assessed by palpation) or\n\nPresence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)\n\nTiredness\nDifficulty sleeping\nItching\nMuscle aches and/or bone pain\nNight sweats\nSweats while awake\nOther""]",0,"['Cohort A', 'Cohort B']",0,0,0,0,0,0,0,0,0,0,0,0
1143,NCT04072289,0,0,0,0,"['0.25D and 0.50D cylinder treatments will be measured and treated by the laser.', '0.25D and 0.50D cylinder treatments will be measured but not treated by the laser. No spherical equivalent will be used.']",Device: Visumax spherocylindrical treatment,"['Low cylinder (treatment)', 'Low cylinder (no treatment)']","['Experimental', 'No Intervention']",0,0,0,0,0,0,0,0,0,0,0
1144,NCT04423770,0,0,0,0,Dentists in the United States,Other: No intervention,U.S. dentists,0,0,0,0,0,0,0,0,0,0,0,0
1145,NCT01358552,0,0,0,0,Subjects who have been prescribed Néevo/NéevoDHA® daily.,Other: Néevo®/ NéevoDHA®,Néevo®/NéevoDHA®,0,0,0,0,0,0,0,0,0,0,0,0
1146,NCT02856646,0,0,0,0,Community Sample,0,Population with Condition,0,0,0,0,0,0,0,0,0,0,0,0
1147,NCT01940679,0,0,0,0,"['Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.', 'Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production', 'Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.', 'Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.']","['Dietary Supplement: encapsulated 600 mg EPA/DHA', 'Dietary Supplement: encapsulated 600 mg EPA/DHA', 'Dietary Supplement: encapsulated 600 mg EPA/DHA', 'Dietary Supplement: encapsulated 600 mg EPA/DHA']","['Fresh meat stick', 'Stored meat stick', 'Fresh pound cake', 'Stored pound cake']","['Experimental', 'Experimental', 'Experimental', 'Experimental']",0,0,0,0,0,0,0,0,0,0,0
1148,NCT02951598,0,0,0,0,"['Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.', 'Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.', 'Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.', 'Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.']","['Drug: Florbetapir F 18 PET Scan', 'Drug: Florbetapir F 18 PET Scan', 'Drug: Florbetapir F 18 PET Scan', 'Drug: Florbetapir F 18 PET Scan']","['MCI (Amyloid Positive)', 'Mild AD Dementia (Amyloid Positive)', 'MCI (Amyloid Negative)', 'Mild Dementia (Amyloid Negative)']","['Other', 'Other', 'Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
1149,NCT02988934,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1150,NCT01028300,"Clinical Investigators may freely present or publish results of the Clinical Investigation in a manner which fairly sets forth the conclusions reached by the Clinical Investigators, but only after the Sponsor has been given the opportunity of reviewing the proposed presentation or publication prior to the intended submission, presentation, or publication date",No,OTHER,Yes,0,Device: ProDisc™-L Total Disc Replacement (TDR),ProDisc L,Other,0,0,0,0,"['<=18 years', 'Between 18 and 65 years', '>=65 years', 'Female', 'Male']",0,0,0,United States,BG000,4
1151,NCT01034865,0,0,0,0,"['Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.', 'Patients with chronic liver disease without evidence of HCC']",0,"['HCC PTS', 'LD']",0,0,0,0,0,0,0,0,0,0,0,0
1152,NCT02352532,0,0,0,0,0,"['Other: Dry Needling', 'Other: Sham Needling', 'Other: Dry Needling']","['Low Back Pain - Dry Needling', 'Low Back Pain - Sham', 'Asymmptomatic - Dry Needling']","['Experimental', 'Sham Comparator', 'Active Comparator']",0,0,0,0,0,0,0,0,0,0,0
1153,NCT03198793,0,0,0,0,Capsules of QGC001 250 mg,Drug: QGC001,QGC001,Experimental,0,0,0,0,0,0,0,0,0,0,0
1154,NCT01112917,0,No,GT60,Yes,Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.,"['Device: VenaTech Convertible Vena Cava Filter', 'Procedure: Vena Cava Filter Conversion']",VenaTech Convertible Vena Cava Filter,Experimental,0,0,0,0,"['Female', 'Male', 'Hispanic or Latino', 'Not Hispanic or Latino', 'Unknown or Not Reported', 'American Indian or Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific Islander', 'Black or African American', 'White', 'More than one race', 'Unknown or Not Reported']",0,0,0,United States,BG000,149
1155,NCT01764269,0,0,0,0,"['Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)', 'Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)']","['Other: text message surveillance for fever', 'Other: text message surveillance for fever']","['inactivated influenza vaccine (IIV)', 'Live attenuated influenza vaccine (LAIV)']","['Other', 'Other']",0,0,0,0,0,0,0,0,0,0,0
1156,NCT03346603,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1157,NCT04281290,0,0,0,0,0,Procedure: Electrochemotherapy - electroporation with Cliniporator Vitae® and chemotherapy drug Bleomycin PHC 15 e. (United States Pharmacopeia - USP),Experimental group,Experimental,0,0,0,0,0,0,0,0,0,0,0
1158,NCT04601103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1159,NCT04600856,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1160,NCT04599907,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1161,NCT04593875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1162,NCT04589507,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1163,NCT04586205,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1164,NCT04585646,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1165,NCT04584788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1166,NCT04584099,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1167,NCT04577898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1168,NCT04577456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1169,NCT04569253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1170,NCT04567186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1171,NCT04562532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1172,NCT04558970,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1173,NCT04558632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1174,NCT04558047,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1175,NCT04557917,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1176,NCT04557891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1177,NCT04556968,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1178,NCT04556474,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1179,NCT04547920,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1180,NCT04547712,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1181,NCT04544670,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1182,NCT04542525,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1183,NCT04540913,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1184,NCT04537013,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1185,NCT04536168,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1186,NCT04534764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1187,NCT04532099,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1188,NCT04529616,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1189,NCT04529109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1190,NCT04524247,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1191,NCT04523545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1192,NCT04513574,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1193,NCT04510857,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1194,NCT04508335,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1195,NCT04502758,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1196,NCT04501146,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1197,NCT04500821,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1198,NCT04499521,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1199,NCT04496752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1200,NCT04493021,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1201,NCT04488666,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1202,NCT04483791,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1203,NCT04476784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1204,NCT04474054,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1205,NCT04469218,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1206,NCT04466930,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1207,NCT04455997,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1208,NCT04455854,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1209,NCT04450108,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1210,NCT04437615,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1211,NCT04422990,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1212,NCT04419714,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1213,NCT04409158,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1214,NCT04403542,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1215,NCT04400643,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1216,NCT04394546,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1217,NCT04388787,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1218,NCT04388722,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1219,NCT04386785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1220,NCT04378764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1221,NCT04377438,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1222,NCT04338971,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1223,NCT04335981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1224,NCT04332640,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1225,NCT04330001,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1226,NCT04324593,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1227,NCT04320823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1228,NCT04319887,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1229,NCT04318132,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1230,NCT04314947,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1231,NCT04314700,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1232,NCT04313725,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1233,NCT04310566,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1234,NCT04307446,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1235,NCT04306744,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1236,NCT04305119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1237,NCT04303273,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1238,NCT04299386,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1239,NCT04299009,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1240,NCT04298359,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1241,NCT04296773,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1242,NCT04295499,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1243,NCT04287036,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1244,NCT04285541,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1245,NCT04281940,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1246,NCT04279522,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1247,NCT04277455,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1248,NCT04263532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1249,NCT04252183,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1250,NCT04247581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1251,NCT04244357,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1252,NCT04243369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1253,NCT04243239,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1254,NCT04239885,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1255,NCT04237207,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1256,NCT04236869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1257,NCT04230486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1258,NCT04224155,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1259,NCT04223609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1260,NCT04220060,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1261,NCT04219891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1262,NCT04211441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1263,NCT04210622,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1264,NCT04207749,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1265,NCT04206839,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1266,NCT04206384,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1267,NCT04203745,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1268,NCT04202419,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1269,NCT04201340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1270,NCT04200898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1271,NCT04196907,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1272,NCT04195581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1273,NCT04194307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1274,NCT04192630,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1275,NCT04189913,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1276,NCT04189081,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1277,NCT04186806,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1278,NCT04184973,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1279,NCT04178720,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1280,NCT04177771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1281,NCT04177212,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1282,NCT04176965,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1283,NCT04175340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1284,NCT04166032,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1285,NCT04162652,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1286,NCT04158466,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1287,NCT04153292,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1288,NCT04152642,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1289,NCT04151992,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1290,NCT04151290,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1291,NCT04141007,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1292,NCT04136158,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1293,NCT04134286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1294,NCT04130490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1295,NCT04127188,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1296,NCT04121754,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1297,NCT04119609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1298,NCT04116879,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1299,NCT04116866,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1300,NCT04112784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1301,NCT04112628,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1302,NCT04112134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1303,NCT04106934,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1304,NCT04096495,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1305,NCT04087395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1306,NCT04085328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1307,NCT04083742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1308,NCT04082078,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1309,NCT04081727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1310,NCT04079842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1311,NCT04079816,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1312,NCT04078490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1313,NCT04073823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1314,NCT04069585,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1315,NCT04068818,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1316,NCT04065659,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1317,NCT04064606,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1318,NCT04060524,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1319,NCT04057105,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1320,NCT04056494,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1321,NCT04055519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1322,NCT04055324,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1323,NCT04054401,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1324,NCT04046627,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1325,NCT04043234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1326,NCT04040933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1327,NCT04036747,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1328,NCT04035161,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1329,NCT04033315,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1330,NCT04032977,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1331,NCT04031989,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1332,NCT04031976,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1333,NCT04030702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1334,NCT04011826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1335,NCT04008836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1336,NCT04005586,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1337,NCT04003831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1338,NCT03999944,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1339,NCT03997357,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1340,NCT03996187,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1341,NCT03995355,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1342,NCT03992768,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1343,NCT03991468,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1344,NCT03972995,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1345,NCT03971721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1346,NCT03969875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1347,NCT03967184,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1348,NCT03964831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1349,NCT03953274,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1350,NCT03950895,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1351,NCT03949335,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1352,NCT03944629,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1353,NCT03942016,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1354,NCT03941912,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1355,NCT03934463,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1356,NCT03934125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1357,NCT03931213,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1358,NCT03925545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1359,NCT03920280,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1360,NCT03918928,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1361,NCT03912584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1362,NCT03911700,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1363,NCT03898778,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1364,NCT03897751,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1365,NCT03897712,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1366,NCT03895034,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1367,NCT03888352,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1368,NCT03872609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1369,NCT03872466,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1370,NCT03871179,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1371,NCT03864848,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1372,NCT03864081,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1373,NCT03862300,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1374,NCT03858140,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1375,NCT03851510,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1376,NCT03839199,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1377,NCT03835026,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1378,NCT03812679,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1379,NCT03805074,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1380,NCT03799549,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1381,NCT03790046,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1382,NCT03789669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1383,NCT03788551,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1384,NCT03782116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1385,NCT03779984,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1386,NCT03771521,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1387,NCT03771352,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1388,NCT03764254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1389,NCT03748823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1390,NCT03748771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1391,NCT03748316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1392,NCT03748264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1393,NCT03736798,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1394,NCT03730480,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1395,NCT03729024,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1396,NCT03728309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1397,NCT03716492,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1398,NCT03713281,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1399,NCT03708393,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1400,NCT03706430,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1401,NCT03704636,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1402,NCT03700372,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1403,NCT03700047,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1404,NCT03696316,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1405,NCT03692741,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1406,NCT03685136,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1407,NCT03682432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1408,NCT03681886,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1409,NCT03681496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1410,NCT03678103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1411,NCT03677388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1412,NCT03670277,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1413,NCT03663010,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1414,NCT03642431,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1415,NCT03641937,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1416,NCT03631550,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1417,NCT03628898,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1418,NCT03617822,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1419,NCT03614130,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1420,NCT03613363,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1421,NCT03611101,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1422,NCT03604900,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1423,NCT03604562,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1424,NCT03604432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1425,NCT03601182,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1426,NCT03600194,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1427,NCT03599271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1428,NCT03589911,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1429,NCT03586167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1430,NCT03578302,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1431,NCT03574259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1432,NCT03564366,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1433,NCT03560141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1434,NCT03550807,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1435,NCT03540576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1436,NCT03538561,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1437,NCT03525704,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1438,NCT03523208,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1439,NCT03508778,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1440,NCT03502200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1441,NCT03500341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1442,NCT03497910,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1443,NCT03488849,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1444,NCT03488238,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1445,NCT03482297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1446,NCT03477370,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1447,NCT03467204,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1448,NCT03465514,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1449,NCT03462576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1450,NCT03451786,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1451,NCT03442842,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1452,NCT03441971,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1453,NCT03441880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1454,NCT03441477,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1455,NCT03439189,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1456,NCT03435224,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1457,NCT03435211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1458,NCT03431883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1459,NCT03423251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1460,NCT03421145,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1461,NCT03418545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1462,NCT03408444,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1463,NCT03388138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1464,NCT03384381,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1465,NCT03372434,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1466,NCT03372343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1467,NCT03371160,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1468,NCT03366194,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1469,NCT03351192,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1470,NCT03345121,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1471,NCT03345017,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1472,NCT03339388,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1473,NCT03336944,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1474,NCT03329794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1475,NCT03323515,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1476,NCT03315117,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1477,NCT03299933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1478,NCT03275532,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1479,NCT03272308,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1480,NCT03269097,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1481,NCT03268356,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1482,NCT03268265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1483,NCT03267134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1484,NCT03257410,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1485,NCT03251079,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1486,NCT03246503,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1487,NCT03242148,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1488,NCT03239574,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1489,NCT03236519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1490,NCT03235791,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1491,NCT03233945,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1492,NCT03230877,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1493,NCT03230747,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1494,NCT03219567,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1495,NCT03198988,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1496,NCT03190564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1497,NCT03182660,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1498,NCT03172949,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1499,NCT03150407,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1500,NCT03148613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1501,NCT03147820,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1502,NCT03147482,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1503,NCT03147417,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1504,NCT03143127,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1505,NCT03142594,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1506,NCT03142581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1507,NCT03138369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1508,NCT03138343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1509,NCT03134989,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1510,NCT03132363,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1511,NCT03132350,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1512,NCT03129152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1513,NCT03128840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1514,NCT03128632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1515,NCT03127566,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1516,NCT03127540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1517,NCT03127527,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1518,NCT03127501,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1519,NCT03127488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1520,NCT03125135,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1521,NCT03125122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1522,NCT03125109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1523,NCT03125096,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1524,NCT03125044,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1525,NCT03124992,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1526,NCT03124953,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1527,NCT03124940,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1528,NCT03124888,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1529,NCT03124849,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1530,NCT03124810,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1531,NCT03124745,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1532,NCT03124732,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1533,NCT03124719,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1534,NCT03124706,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1535,NCT03124264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1536,NCT03124251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1537,NCT03123380,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1538,NCT03123341,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1539,NCT03122379,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1540,NCT03120702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1541,NCT03100760,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1542,NCT03098602,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1543,NCT03073148,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1544,NCT03072186,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1545,NCT03066063,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1546,NCT03038074,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1547,NCT03035318,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1548,NCT03034902,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1549,NCT03021707,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1550,NCT03021473,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1551,NCT03019107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1552,NCT03017742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1553,NCT03003767,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1554,NCT02995421,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1555,NCT02986789,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1556,NCT02972892,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1557,NCT02970799,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1558,NCT02966210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1559,NCT02957071,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1560,NCT02956928,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1561,NCT02948751,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1562,NCT02938637,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1563,NCT02922621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1564,NCT02919566,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1565,NCT02918942,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1566,NCT02916823,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1567,NCT02913560,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1568,NCT02911376,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1569,NCT02910674,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1570,NCT02907203,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1571,NCT02904382,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1572,NCT02888626,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1573,NCT02872844,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1574,NCT02870959,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1575,NCT02870881,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1576,NCT02863796,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1577,NCT02863432,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1578,NCT02862080,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1579,NCT02858089,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1580,NCT02856490,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1581,NCT02849847,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1582,NCT02842970,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1583,NCT02841397,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1584,NCT02833571,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1585,NCT02811328,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1586,NCT02810080,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1587,NCT02805933,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1588,NCT02805777,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1589,NCT02800057,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1590,NCT02799342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1591,NCT02799329,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1592,NCT02795689,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1593,NCT02787343,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1594,NCT02784431,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1595,NCT02771119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1596,NCT02764580,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1597,NCT02761759,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1598,NCT02756260,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1599,NCT02746289,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1600,NCT02746120,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1601,NCT02719444,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1602,NCT02716155,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1603,NCT02712931,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1604,NCT02711254,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1605,NCT02699021,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1606,NCT02698787,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1607,NCT02698397,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1608,NCT02697604,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1609,NCT02686450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1610,NCT02684110,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1611,NCT02680964,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1612,NCT02680860,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1613,NCT02662049,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1614,NCT02638883,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1615,NCT02634996,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1616,NCT02634554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1617,NCT02634125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1618,NCT02631213,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1619,NCT02626624,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1620,NCT02624739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1621,NCT02622919,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1622,NCT02599519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1623,NCT02597296,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1624,NCT02596464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1625,NCT02579486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1626,NCT02576210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1627,NCT02561052,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1628,NCT02553395,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1629,NCT02548429,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1630,NCT02543814,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1631,NCT02540577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1632,NCT02540564,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1633,NCT02535234,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1634,NCT02525783,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1635,NCT02517645,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1636,NCT02506400,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1637,NCT02495116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1638,NCT02480829,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1639,NCT02474784,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1640,NCT02474771,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1641,NCT02474758,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1642,NCT02458378,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1643,NCT02455063,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1644,NCT02441634,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1645,NCT02436005,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1646,NCT02430441,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1647,NCT02405871,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1648,NCT02403167,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1649,NCT02396914,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1650,NCT02388425,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1651,NCT02383082,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1652,NCT02380716,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1653,NCT02380014,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1654,NCT02365545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1655,NCT02365467,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1656,NCT02364375,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1657,NCT02353377,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1658,NCT02343068,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1659,NCT02340832,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1660,NCT02327598,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1661,NCT02325609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1662,NCT02322840,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1663,NCT02312141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1664,NCT02300974,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1665,NCT02289534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1666,NCT02284321,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1667,NCT02283125,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1668,NCT02280577,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1669,NCT02275624,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1670,NCT02272114,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1671,NCT02271087,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1672,NCT02268227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1673,NCT02255539,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1674,NCT02239263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1675,NCT02231034,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1676,NCT02223663,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1677,NCT02218450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1678,NCT02195362,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1679,NCT02195128,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1680,NCT02191800,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1681,NCT02187458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1682,NCT02167880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1683,NCT02166073,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1684,NCT02142465,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1685,NCT02142374,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1686,NCT02142023,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1687,NCT02141334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1688,NCT02134236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1689,NCT02124538,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1690,NCT02108275,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1691,NCT02089646,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1692,NCT02086812,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1693,NCT02085174,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1694,NCT02082847,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1695,NCT02070601,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1696,NCT02036385,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1697,NCT02020447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1698,NCT02006251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1699,NCT02004249,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1700,NCT02003105,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1701,NCT01989390,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1702,NCT01989377,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1703,NCT01988727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1704,NCT01988025,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1705,NCT01984151,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1706,NCT01973621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1707,NCT01966211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1708,NCT01957982,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1709,NCT01951131,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1710,NCT01950767,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1711,NCT01940458,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1712,NCT01940211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1713,NCT01937000,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1714,NCT01936987,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1715,NCT01916083,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1716,NCT01906736,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1717,NCT01905241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1718,NCT01896141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1719,NCT01894698,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1720,NCT01883557,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1721,NCT01882309,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1722,NCT01877369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1723,NCT01874925,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1724,NCT01867008,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1725,NCT01859975,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1726,NCT01854879,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1727,NCT01847846,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1728,NCT01835769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1729,NCT01835366,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1730,NCT01827488,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1731,NCT01820741,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1732,NCT01801995,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1733,NCT01801241,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1734,NCT01795807,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1735,NCT01795118,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1736,NCT01792869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1737,NCT01790867,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1738,NCT01787981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1739,NCT01777880,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1740,NCT01773941,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1741,NCT01773265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1742,NCT01747265,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1743,NCT01738230,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1744,NCT01738165,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1745,NCT01733264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1746,NCT01733251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1747,NCT01724541,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1748,NCT01721122,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1749,NCT01715454,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1750,NCT01700764,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1751,NCT01697813,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1752,NCT01697774,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1753,NCT01674400,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1754,NCT01670006,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1755,NCT01662479,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1756,NCT01660113,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1757,NCT01658189,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1758,NCT01652846,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1759,NCT01643200,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1760,NCT01640795,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1761,NCT01630707,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1762,NCT01629836,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1763,NCT01627405,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1764,NCT01614925,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1765,NCT01613742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1766,NCT01610505,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1767,NCT01610349,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1768,NCT01607606,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1769,NCT01604967,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1770,NCT01597271,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1771,NCT01591369,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1772,NCT01582386,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1773,NCT01575210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1774,NCT01564589,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1775,NCT01560156,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1776,NCT01558609,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1777,NCT01556750,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1778,NCT01546831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1779,NCT01546584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1780,NCT01533831,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1781,NCT01533103,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1782,NCT01532752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1783,NCT01532440,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1784,NCT01524263,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1785,NCT01515618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1786,NCT01513512,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1787,NCT01499030,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1788,NCT01494376,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1789,NCT01480570,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1790,NCT01476826,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1791,NCT01473134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1792,NCT01470079,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1793,NCT01464580,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1794,NCT01463618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1795,NCT01462955,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1796,NCT01450540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1797,NCT01443299,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1798,NCT01443286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1799,NCT01442389,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1800,NCT01436669,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1801,NCT01436461,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1802,NCT01414491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1803,NCT01414270,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1804,NCT01412112,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1805,NCT01408017,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1806,NCT01403584,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1807,NCT01392261,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1808,NCT01379794,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1809,NCT01374243,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1810,NCT01370785,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1811,NCT01367171,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1812,NCT01365689,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1813,NCT01358682,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1814,NCT01336868,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1815,NCT01313351,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1816,NCT01313195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1817,NCT01311726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1818,NCT01307709,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1819,NCT01297751,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1820,NCT01286792,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1821,NCT01258400,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1822,NCT01246115,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1823,NCT01240733,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1824,NCT01239576,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1825,NCT01234480,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1826,NCT01230398,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1827,NCT01201889,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1828,NCT01194752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1829,NCT01194739,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1830,NCT01194726,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1831,NCT01183195,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1832,NCT01180257,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1833,NCT01171066,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1834,NCT01166607,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1835,NCT01164527,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1836,NCT01158963,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1837,NCT01150227,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1838,NCT01148251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1839,NCT01147094,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1840,NCT01145651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1841,NCT01145378,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1842,NCT01143116,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1843,NCT01140919,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1844,NCT01127347,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1845,NCT01112475,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1846,NCT01108822,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1847,NCT01106222,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1848,NCT01103869,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1849,NCT01100983,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1850,NCT01098682,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1851,NCT01097824,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1852,NCT01092871,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1853,NCT01077141,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1854,NCT01070992,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1855,NCT01067040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1856,NCT01062464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1857,NCT01062412,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1858,NCT01062217,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1859,NCT01057134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1860,NCT01043497,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1861,NCT01039064,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1862,NCT01037439,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1863,NCT01030588,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1864,NCT01029028,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1865,NCT01022554,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1866,NCT01016236,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1867,NCT01008202,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1868,NCT01000454,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1869,NCT00993772,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1870,NCT00990483,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1871,NCT00990210,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1872,NCT00986908,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1873,NCT00981188,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1874,NCT00979498,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1875,NCT00979030,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1876,NCT00969748,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1877,NCT00968474,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1878,NCT00961519,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1879,NCT00960947,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1880,NCT00957632,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1881,NCT00957138,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1882,NCT00956618,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1883,NCT00955331,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1884,NCT00946075,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1885,NCT00944411,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1886,NCT00942942,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1887,NCT00935974,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1888,NCT00932789,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1889,NCT00924716,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1890,NCT00911040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1891,NCT00906958,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1892,NCT00906815,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1893,NCT00906009,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1894,NCT00905749,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1895,NCT00903058,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1896,NCT00901667,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1897,NCT00900705,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1898,NCT00889746,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1899,NCT00878982,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1900,NCT00877916,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1901,NCT00865930,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1902,NCT00865735,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1903,NCT00863486,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1904,NCT00863447,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1905,NCT00858091,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1906,NCT00850434,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1907,NCT00850109,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1908,NCT00846820,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1909,NCT00843752,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1910,NCT00840619,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1911,NCT00824018,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1912,NCT00821769,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1913,NCT00820040,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1914,NCT00819130,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1915,NCT00818922,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1916,NCT00810498,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1917,NCT00810459,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1918,NCT00809406,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1919,NCT00806052,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1920,NCT00802750,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1921,NCT00800891,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1922,NCT00799981,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1923,NCT00794534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1924,NCT00791414,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1925,NCT00790621,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1926,NCT00789334,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1927,NCT00788450,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1928,NCT00788437,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1929,NCT00782119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1930,NCT00781651,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1931,NCT00781222,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1932,NCT00780065,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1933,NCT00779623,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1934,NCT00777283,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1935,NCT00776893,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1936,NCT00776815,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1937,NCT00776152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1938,NCT00773903,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1939,NCT00773721,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1940,NCT00769340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1941,NCT00767910,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1942,NCT00766727,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1943,NCT00764491,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1944,NCT00764452,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1945,NCT00760643,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1946,NCT00759694,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1947,NCT00758979,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1948,NCT00758875,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1949,NCT00758095,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1950,NCT00756496,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1951,NCT00754598,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1952,NCT00748917,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1953,NCT00748033,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1954,NCT00747266,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1955,NCT00739245,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1956,NCT00732264,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1957,NCT00732134,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1958,NCT00728702,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1959,NCT00727805,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1960,NCT00727688,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1961,NCT00726297,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1962,NCT00726024,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1963,NCT00725816,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1964,NCT00725699,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1965,NCT00716313,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1966,NCT00690742,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1967,NCT00681057,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1968,NCT00680251,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1969,NCT00678808,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1970,NCT00676546,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1971,NCT00676078,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1972,NCT00670137,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1973,NCT00660556,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1974,NCT00659139,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1975,NCT00653211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1976,NCT00639340,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1977,NCT00630526,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1978,NCT00617630,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1979,NCT00617162,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1980,NCT00616226,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1981,NCT00615342,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1982,NCT00608647,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1983,NCT00597571,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1984,NCT00591513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1985,NCT00589069,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1986,NCT00588601,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1987,NCT00587613,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1988,NCT00587509,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1989,NCT00586456,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1990,NCT00579176,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1991,NCT00578513,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1992,NCT00578487,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1993,NCT00576953,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1994,NCT00561847,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1995,NCT00542477,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1996,NCT00529685,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1997,NCT00506220,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1998,NCT00448812,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1999,NCT00350259,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
